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ABSTRACT 
The blood-brain barrier (BBB) constitutes the interface between the blood and the 
brain tissue. Its primary function is to maintain the tightly controlled 
microenvironment of the brain. Models of the BBB are useful for studying the 
development and maintenance of the BBB as well as diseases affecting it. Furthermore, 
BBB models are important tools in drug development and support the evaluation of 
the brain-penetrating properties of novel drug molecules. Currently used in vitro 
models of the BBB include immortalized brain endothelial cell lines and primary brain 
endothelial cells of human and animal origin. Unfortunately, these cell lines and 
primary cells have failed to recreate physiologically relevant control of transport in 
vitro. Human-induced pluripotent stem cell (iPSC)-derived brain endothelial cells have 
proven a promising alternative source of brain endothelial-like cells that replicate tight 
cell layers with low para-cellular permeability. Given the possibility to generate large 
amounts of iPSC-derived brain endothelial cells they are a feasible alternative when 
modelling the BBB in vitro.  
This thesis aimed to develop iPSC-derived models of the BBB that display a barrier 
like phenotype and characterize these models in terms of specific properties. The BBB 
model development was based on investigations into mechanisms important for barrier 
formation in iPSC-derived endothelial cells and development of high-quality 
supporting cells. The possibilities to use the model in drug discovery, and in 
determination of brain penetrating capacity of drug substances were specifically 
considered. These studies have increased knowledge of molecular mechanisms behind 
the restricted permeability across iPSC-derived endothelial cells and identified 
transcriptional changes that occur in iPSC-derived endothelial cells upon coculture 
with relevant cell types of the neurovascular unit. Furthermore, high quality iPSC-
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derived astrocytic cells were developed, and the biological relevance and model 
diversity between astrocytic models were evaluated. Both astrocytes and brain 
endothelial cells have been adapted to xeno-free culture conditions and used in the 
BBB models, demonstrating a xeno-free BBB model. Finally, a more biologically 
relevant microphysiological dynamic BBB model was generated. This model 
demonstrated improved permeability modelling and compatibility with high-
throughput substance permeability screening.  
Taken together these results show that iPSC-derived BBB models are useful for 
studying BBB-specific properties in vitro and that both marker expression and 
functional evaluation of iPSC-derived cells are important in assessing cell identity and 
cell quality. In addition, these results show that iPSC derived BBB models are feasible 
for high-throughput permeability studies.  
Keywords: Blood-brain barrier, iPSC, in vitro model, permeability 
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SAMMANFATTNING PÅ SVENSKA 
Blod-hjärnbarriärens (BHB) huvudsakliga uppgift är att skydda det känsliga centrala 
nervsystemet från potentiellt skadliga substanser som cirkulerar i blodet. Genom att 
begränsa permeabiliteten av blodkärlen i hjärnan bibehålls den specifika miljön i 
centrala nervsystemet som krävs för att hjärnan ska fungera optimalt. Eftersom BHB 
är en vital del av det centrala nervsystemet är det svårt att studera BHB direkt i 
människokroppen utan att göra skada. Därför behövs modeller.  
 
Modeller av BHB är viktiga för att studera utvecklingen och upprätthållandet av BHB 
och även för att förutsäga i vilken utsträckning nya medicinska molekyler kommer att 
ta sig in i centrala nervsystemet. Ofta används cellbaserade BHB-modeller uppbyggda 
av hjärnendotelceller med eller utan pericyter och nervceller. Immortaliserade cellinjer 
av humana hjärnendotelceller och primära hjärnendotelceller från djur har använts. 
Tyvärr uppvisar dessa cellmodeller inte en tät barriär likt den i människa när de odlas 
i laboratoriemiljö (in vitro). Det finns även bevis för att BHB skiljer sig åt mellan 
människa och djur, vilket medför att modeller som baseras på djurceller kan vara 
missvisande. Därtill pågår stora ansträngningar för att reducera djurförsök inom 
forskningen. Sammanfattningsvis behövs det nya och bättre in vitro-modeller för att 
ingående kunna studera egenskaper hos den mänskliga BHB i laboratorier.  
 
Mänskliga inducerade pluripotenta stamceller (iPSC) skapas genom att celler från en 
vuxen person återprogrammeras till ett tidigt utvecklingsstadium där dessa kan bilda 
alla olika celltyper i kroppen. Hjärnendotelceller som bildats från iPSC har visat sig 
återskapa en mycket tät barriär i laboratoriemiljö. En av de mest typiska egenskaperna 
för iPSC är att de har hög delningsfrekvens. Genom att använda iPSC kan stora 
mängder mänskliga hjärnendotelceller med barriäregenskaper lika de i BHB 
produceras och användas för att studera specifika egenskaper hos den mänskliga BHB.  
 
Syftet med denna avhandling var att utveckla BHB-modeller från iPSC och undersöka 
BHB-specifika egenskaper hos dessa modeller. Modellerna har utvärderats med 
avseende på faktorer som påverkar barriäregenskaper hos hjärnendotelceller. Särskild 
hänsyn har tagits till modellernas förmåga att användas i läkemedelsutveckling för att 
studera hjärnexponeringen av nya medicinska molekyler. Specifik identitet för olika 
celltyper har utvärderats genom att undersöka uttryck av gener och protein som 
kännetecknar dessa celltyper. Funktionalitet hos cellerna har studerats genom att 
undersöka deras förmåga att utföra processer som normalt utförs av dessa celler i 
kroppen. Både passiv och aktiv permeabilitet över BHB-modellen studerades med 
hjälp av fluorescerande verktygssubstanser och kända läkemedelssubstanser.  
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När hjärnendotelceller från iPSC odlas tillsammans med pericyter och nervceller 
reducerades permeabilitet i BHB-modeller. Avhandlingens resultat har ökat 
förståelsen för vilka molekylära mekanismer som bidrar till denna reducerade 
permeabilitet. Högkvalitativa astrocyter har skapats från iPSC och jämförts med andra 
astrocytmodeller för att utvärdera deras relevans som human astrocytmodell samt för 
att förstå skillnader mellan olika, vanligt förekommande, astrocytmodeller. Produktion 
av både astrocyter och hjärnendotelceller från iPSC har anpassats till 
odlingsbetingelser utan användning av animaliska biprodukter. Astrocyter och 
hjärnendotel celler har sedan använts i BHB-modeller för att skapa en helt human 
modell. Slutligen har BHB-modellen förbättrats ytterligare genom utveckling av en 
mer biologiskt relevant modell som återskapar den tredimensionella miljön som råder 
i hjärnans blodkärl. I denna modell växer hjärnendotelceller i ett artificiellt kärl där de 
fysiska påfrestningarna av blodflöde simuleras med hjälp av genomströmning av 
endotelcellskärlet. Modelleringen av specifik transport som framför allt påverkar 
läkemedelssubstanser förbättrades i denna modell. Denna modell lämpar sig även för 
storskalig permeabilitetsanalys.  
 
Sammantaget visar resultaten i denna avhandling att BHB-modeller som är uppbyggda 
av celler från iPSC är mycket användbara för att studera BHB-specifika egenskaper i 
laboratoriemiljö. Dessutom tydliggörs hur analyser av både proteinuttryck och 
funktionalitet är viktigt för att utvärdera kvaliteten hos specifika celltyper, samt för 
analysen av deras förmåga att utföra sina respektive uppgifter. Därtill visas att 
storskalig analys av BHB-permeabilitet är möjlig med BHB-modeller från iPSC. 
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1 THE BIOLOGY OF THE BLOOD-BRAIN 
BARRIER  
The blood-brain barrier (BBB) is the interface between the blood and the brain tissue. 
Its primary function is to maintain the tightly controlled microenvironment of the 
brain. The barrier consists of endothelial cells with properties specific to the central 
nervous system (CNS) (1). These brain endothelial cells control the permeability of 
the barrier. At the brain side of the endothelial cells, the extracellular basement 
membrane (BM) surrounds the endothelial cells and embeds the pericytes. Astrocytic 
end-feet are in contact with the basal membrane. This unit of astrocytes, pericytes, 
basal membrane and endothelial cells is often referred to as the neurovascular unit 
(NVU, Figure 1) (1). Together these components make up the BBB and govern its 
development, maintenance and function. The paracellular tightness of the endothelial 
cells in the BBB acts as a physical barrier for cells, proteins and water-soluble agents. 
Transporter proteins control nutrient supply and permeability of small molecules in a 
specific manner. The BBB is a highly dynamic structure, which is regulated by the 
interactions of the cellular and extra cellular matrix (ECM) parts of the NVU. Isolated 
primary brain endothelial cells rapidly lose their BBB properties when cultured in vitro 
(2), consequently it is plausible that the BBB properties are not intrinsic to the brain 
endothelial cells but rather depend on the specific microenvironment that all 
components of the NVU create together. 
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Figure 1. The neurovascular unit. Endothelial cells are linked together via tight 
junctions. On the brain side of the endothelial cell layer the basement membrane 
surrounds the endothelial cells and embeds the pericytes. Astrocytic end-feet are in 
contact with the endothelial cells.  
 Early brain development 
The human brain is an immensely complex structure that consists of more than 100 
billion neurons (3). To support these neurons, different types of glia cells are present, 
mainly astrocytes, oligodendrocytes and microglia. While the functions of 
oligodendrocytes and microglia are well characterized as myelinating and immune 
surveillance respectively, the functions of astrocytes are more diverse, and the list of 
tasks performed by astrocytes are growing continuously. For example, astrocytes 
maintain brain homeostasis, support accurate synaptic signalling, govern synaptic 
formation and promote BBB formation and maintenance (4).  
Human brain development is a lengthy process that begins in the third gestation week 
(GW) when gastrulation occurs (3). In the gastrulation phase, the three germ layers; 
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ectoderm, mesoderm, and endoderm, are formed. The ectodermal cells give rise to the 
CNS, the mesodermal cells give rise to muscle cells, blood cells and the blood vessels 
that make up the BBB, and the endoderm give rise to many of the cell types that make 
up internal organs such as lung cells and gastrointestinal tracts. The neuroectoderm 
develops through three distinct phases, the development of the neural plate, formation 
of the neural groove, and finally, folding into the neural tube, which buds of from the 
ectodermal tissue (3). The neural tube is regionally specified, the rostral part will give 
rise to the brain and the caudal part will give rise to the hind-brain and spinal tube, in 
addition the hollow middle part of the neural tube will give rise to the ventricles and is 
thus referred to as the ventricular zone. Already at this stage, the vascularization of the 
neuroectoderm and the development of the BBB are initiated. 
 Blood-brain barrier development  
The development of the BBB begins when vessels start to invade the developing 
neuroectoderm (1). Neural progenitors secrete the strongly angiogenic factor vascular 
endothelial growth factor (VEGF), which guides sprouting of vessels into the neural 
tissue (5). Neural progenitors also secrete WNT, which is necessary for endothelial 
cell migration and induces expression of BBB associated genes, such as the glucose 
transporter Glut-1 and tight junction proteins in the endothelial cells (6). Downstream 
signalling from WNT is essential for vascularization of the CNS but not peripheral 
tissues (6), suggesting a specific role of WNT signalling in development of the brain 
vasculature. In addition, WNT-mediated signalling deficits have been identified as a 
cause of BBB disruption in iPSC-derived endothelial cells from Huntington’s disease 
patients, further emphasizing its importance in BBB development (7). Permeability 
restriction occurs already early in development and rodent studies show that the early 
embryonic BBB prevents leakage of proteins from the blood to the brain (8). Similar 
restriction of blood to brain permeability was recently confirmed in human early 
embryos. The first vessels penetrating into the brain parenchyma in the human 
embryo restricts permeability of blood-derived molecules and are immunopositive 
for claudin-5, suggesting that even the earliest brain blood vessels at GW five have 
BBB characteristics (9). Cues from astrocytes and pericytes are essential in BBB 
development, and lack of such signals are linked to severe abnormalities of the BBB 
(10, 11). Sonic hedgehog (SHH)-signalling is important for BBB formation and SHH 
knockout mice display embryonic lethality (10). The vascularization of their CNS is 
complete but expression of tight junction (TJ) proteins is reduced, suggesting that SHH 
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is important for BBB maturation and tightening. This effect is proposed to be astrocyte-
mediated as SHH is produced and released by astrocytes. Furthermore, SHH-signalling 
is important in both embryonic BBB development and adult BBB immunocompetence 
(10). Most of the mature astrocytes develop after birth (4). Consequently, astrocyte-
dependent changes to BBB function is likely to continue after birth.  
 Brain endothelial cells  
While only making up 2% of the total body mass, the brain consumes about 20% of 
the glucose and oxygen. To support this massive claim of energy and oxygen the 
cerebral blood vessel network is enormous. The blood flow is rapidly increased at sites 
of activity in the brain to accommodate the high energy demand, this is known as 
neurovascular coupling (1). Brain endothelial cells make up the micro-vessels of the 
brain and have features that differentiate them from endothelial cells in other organs. 
Brain endothelial cells have longer continuous stretches of TJs, higher number of 
mitochondria, no fenestrae (small pores) and low pinocytic activity (12-14). All of 
these features contribute to the brain endothelial cell capacity to restrict permeability 
and act as a selective barrier. TJs are important structures in brain endothelial cells that 
separate the blood face from the brain face of the cells. TJ structure and function are 
further discussed in section 2.1. The different faces of the endothelial cells have 
distinct properties, making endothelial cells polarized. TJ restriction of water-soluble 
molecules in the paracellular space cause high trans-endothelial electrical resistance 
(TEER), a hallmark of brain endothelial cells. Physiological brain TEER is estimated 
to be above 1000Ohm x cm2 compared with 2-20Ohm x cm2 in the majority of the 
body (15). TJ proteins, such as claudin-5, occludin and specific transporters, such as 
P-glycoprotein (P-gp) and Glut-1 are often used as markers of brain endothelial cells. 
The study of brain endothelial cells has been hampered by the difficulty to obtain 
human primary brain endothelial cells from healthy individuals and the fact that human 
primary brain endothelial cells and immortalized bran endothelial cell lines do not 
maintain barrier restriction capacity in vitro (2). Primary endothelial cells isolated from 
animals such as pigs and rats retain fairly tight barriers in vitro and can be useful tools 
to study paracellular permeability (2, 16). However, the restrictive capacity in vivo and 
the expression of specific transporters are different between species (17, 18). Hence, 
to be able to predict and study the human BBB a human model is highly preferable.  
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 Astrocytes  
Astrocytes or astroglia are at least as abundant as neurons in the adult human brain 
(19), and the number of astrocytes has even been speculated to be one of the features 
explaining human cognitive abilities (4). Astrocytes are a very diverse cell type, both 
morphologically, molecularly and functionally (20). During development of the human 
brain, astrocytes in the cerebral cortex are derived from four distinct progenitor 
populations: radial glia, subventricular zone progenitors, locally proliferating glia and 
neuron glia antigen 2 (NG2) glia. To what extent each of these four progenitor 
populations contribute to the production of glia remains elusive. Although, it is clear 
that each of these subpopulations of progenitors contributes to the production of 
astrocytes at distinct stages of development and at different locations (19). The 
specifics of the astrocytic developmental process are not yet fully understood. One of 
the underlying reasons for this lack of understanding is the absence of well-
characterized markers to study astrocytes and their progenitors during development. 
Specific functional and molecular profiles of astrocytes depend on signalling from 
surrounding cells, astrocytic diversity and heterogeneity are defined by both regional 
identity and functional input from surrounding neurons (21). Microarray analysis has 
revealed a small number of genes that are expressed by most astrocytes, while 
expression of other genes is specific to astrocytes in certain brain regions (22). 
The understanding of astrocyte functions has evolved over time from being considered 
as a passive helper cell to the insight that astrocytes play a crucial role in development, 
maintenance and aging of the CNS. Astrocytes are key players in the CNS and one 
astrocyte domain can contain many million synapses (20). Astrocytes regulate the 
formation of synapses, control synaptic signalling (23), and support rapid and accurate 
synaptic signalling by regulating availability of nutrients and neurotransmitters (24, 
25). Glutamate is the most abundant excitatory neurotransmitter. Glutamate uptake by 
astrocytes serve as a protective mechanism for excitotoxicity in adjacent neurons 
(25). By removing excess glutamate from the synaptic cleft, the astrocytes maintain 
homeostasis and signalling fidelity in the synapse. Glutamate is taken up, mainly, 
via the EAAT1 and EAAT2 transporters and is then converted to glutamine by 
glutamine synthetase (GLUL) (Figure 2). Glutamine can subsequently be exported 
from the astrocyte via the glutamine exporters SNAT3, SNAT5, ASCT2 and be 
reused by the neurons. Glutamate uptake does not only serve as a protective 
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mechanism for neurons but also activates glycolysis and glucose uptake in 
astrocytes. 
Figure 2.  Glutamate metabolism. Excess glutamate (GLU) in the synaptic cleft is 
taken up into the astrocyte by EAAT1 and EAAT2. In the astrocyte, glutamate is 
converted to glutamine (GLN) by glutamine synthetase (GLUL). Glutamine can then 
be transported out of the astrocyte by glutamine exporters SNAT3, SNAT5 and 
ASCT2 and be reused in the neuron.   
Through their end-feet, astrocytes are in close proximity to brain endothelial cells and 
affect the development and maintenance of the BBB through physical interaction and 
secretion of signalling molecules (26, 27). Astrocytes produce a range of molecules 
that are associated with the BBB phenotype and proper differentiation of brain 
endothelial cells, including components of the BM, glia-derived neurotrophic factor 
(GDNF), VEGF, apolipoprotein E (apoE), transforming growth factor beta (TGF-β), 
inter leukin 6 (IL6) and angiopoietin 1 (Ang-1) (1, 27). Furthermore, SHH produced 
by astrocytes cause upregulation of TJ components and reduced permeability in brain 
endothelial cells (10). Astrocytes also help regulate the blood flow within the brain 
through calcium signalling in their end-feet (28). Many pathological changes in the 
CNS are accompanied by astrocyte activation, commonly identified by increased cell 
In vitro models of the blood-brain barrier using iPSC-derived cells 
7 
body volume and upregulation of intermediate filament proteins, such as glial fibrillary 
acid protein (GFAP) and vimentin (29). Activation of astrocytes and subsequent 
production of cytokines and pro-inflammatory substances in the brain can be 
protective, however, there is evidence that prolonged activation has detrimental effects 
in many CNS trauma and neurodegenerative conditions (29). The production of 
cytokines and inflammatory molecules from activated astrocytes are likely to influence 
the closely connected brain vasculature and thus the BBB. Reactive astrocytes have 
been suggested to increase secretion of both BBB promoting and disrupting factors 
(10, 30). However, the understanding of how reactive astrocytes influence the BBB in 
vivo is still poor. 
 Pericytes 
There is general consensus that pericytes are a highly diverse cell type with different 
subtypes having different functions and characteristics. Interestingly, while most 
pericytes are believed to be of mesodermal origin, studies in birds have suggested that 
CNS pericytes derive from the neural crest (31). Due to the ambiguity of universal 
pericyte properties, finding a gold standard protein marker to identify these cells has 
been challenging. As such, the identification of pericytes relies on a combination of 
morphological criteria and assessment of marker expression. Expression of proteins, 
such as platelet derived growth factor receptor beta (PDGFRβ), NG2, caldesmon, 
CD13 and CD146, is commonly used to identify pericytes. Characterization of 
different subtypes of pericytes are underway. Vitronectin and fork head transcription 
factors FOXF2 and FOXC1, have been shown to be expressed specifically in brain 
pericytes (32-34). In addition to their brain pericyte specific expression, FOXF1 and 
FOXC1 have been shown to influence BBB development.  
At the BBB the pericytes ensheath the endothelial cells. Pericytes are believed to play 
a specific role in the neurovasculature, as neural tissue has higher pericyte coverage of 
the vasculature compared with other organs. Neural tissue has up to one pericyte per 
one endothelial cell (35). Additionally, pericyte coverage correlate positively with 
endothelial barrier properties of different tissues. Pericytes have a diverse set of 
functions, they aid in angiogenesis and microvasculature stabilization, regulate 
capillary diameter and phagocyte toxic compounds (35). Pericytes produce many of 
the BM components and in that way contribute further to the structure of the BBB (36). 
Large parts of the current knowledge around pericyte function come from studies in 
pericyte-deficient rodents. These rodents show a number of BBB abnormalities, such 
Delsing, Louise 
8 
as increased permeability, increased transcytosis and irregular TJs (11). Studies show 
that developing endothelial cells attract pericytes by PDGFβ-signalling, leading to 
pericyte proliferation and co-migration with endothelial cells (11). Pericytes then 
contribute to brain endothelial cell specific maturation such as formation of TJs, 
reduced vesicle trafficking and reduced permeability (11). Human in vivo studies have 
shown increased cerebrospinal fluid (CSF) markers of pericyte damage and BBB 
breakdown in cognitive impairment patients compared to healthy individuals (37). In 
summary, pericytes play an essential role in both BBB formation and maintenance, but 
many of the mechanisms behind pericyte influence on the BBB are still unknown.  
 Neurons and microglia 
Both neurons and microglia affect the BBB, however their contributions are less 
studied than those of pericytes and astrocytes. Microglia are the innate immune cells 
of the brain. Despite their name and stellate morphology, they do not share the common 
neural stem cells origin with neurons, astrocytes and oligodendrocytes. Mouse studies 
suggest that microglia progenitors originate from the yolk sack and migrate into the 
CNS during early embryogenesis, later, these cells proliferate to populate the CNS 
with microglia (38). Microglia invasion of the CNS precedes vascular sprouting into 
the tissue, but when vessels appear, endothelial cells and microglia are in close 
proximity to each other. Microglia have been suggested to play a role in both 
endothelial cell stability and angiogenesis during the development of the brain 
vasculature (39). Microglia become activated in response to injury and immunological 
stimulation. Active microglia can affect BBB stability and increase the permeability 
across the BBB. Studies of rodent in vitro models have suggested that these effects 
depend on reactive oxygen species (40) and tumour necrosis factor alpha (TNFα) (41) 
released by activated microglia. Microglia are important players in BBB formation and 
maintenance in vivo, however, as immunological challenges are kept to a minimum in 
in vitro BBB models, microglial contributions were not investigated in this thesis.  
Neurons make up the main signalling networks of the brain. Neuronal signalling 
requires large amounts of energy and signalling from the neurons affects the blood 
flow through the brain vasculature to ensure enough energy supply. TJ stabilization 
was observed in cocultures of brain endothelial cells and neurons. Brain endothelial 
cells in the coculture were also induced to synthesize and sort occludin to the surface 
(42), indicating that the stabilization of TJs in coculture with neurons may be an effect 
of increased occludin production. Neurons and astrocytes are tightly coupled, 
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astrocytes support correct signalling environment for neurons and neuronal presence 
aids in astrocyte maturation (21, 23). Hence, the effects that neurons have on the BBB 
are likely to be both direct signalling from the neurons to the endothelium and 
secondary effects that arise via changes that neurons promote in the astrocytes. In this 
thesis, neuron cocultures were performed in the in vitro BBB models, however their 
specific contributions were not examined in detail. 
 The basement membrane  
The BM is the non-cellular component of the BBB, it is a specific extracellular matrix 
that surrounds the endothelial cells. The BM contains highly conserved proteins, and 
consists mainly of laminin, collagen IV, perlecan, and nidogen (43, 44). The BM 
contributes to structural support and signalling by binding growth factors and 
neurotrophic factors such as fibroblast growth factor (FGF), VEGF and GDNF (27, 
45, 46). Endothelial cells, pericytes and astrocytes secrete the proteins, which together, 
make up the BM (36, 44, 47, 48). Laminins are the most abundant component of the 
BM. In addition to their structural functions, laminins play an essential role in the 
organization of the BM and the regulation of cell behaviour (47-49), hence the BM 
modulation in this work has focused on laminins. Laminins are multidomain, 
heterotrimeric glycoproteins, composed of three different subunits; an α-chain, β-chain 
and γ-chain, combined and expressed in at least 16 different isoforms in the human 
body (50). The physical, topological, and biochemical expression of the different 
laminin isoforms in the BM is heterogeneous and laminin expression changes during 
development. Without the right combination of laminin isoforms, cells and tissues 
become dysfunctional. Brain endothelial cells generate laminins 411 and 511 (47) 
whereas astrocytes produce laminins 111, 211 (48). Furthermore, mouse studies 
suggest that laminin alpha 5 is more highly expression in brain than in the periphery 
and that it is important in protecting the brain vasculature from mononuclear 
infiltration (47). Laminin 521 has been shown to be specifically important for astrocyte 
migration and vascularization in the retina (51). All the above laminin isoforms are 
also expressed by the primary brain capillary pericytes (47, 49, 52). Effects of culture 
on de-cellularized ECM from pericytes, astrocytes and brain capillary endothelial cells 
on brain endothelial cell differentiation from iPSC was recently investigated (53). It 
was concluded that the de-cellularized ECM from astrocytes had the most beneficial 
effects on brain endothelial cell differentiation, however, this was not significantly 
different from using fibronectin. iPSC-derived brain endothelial cells did not adhere to 
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de-cellularized pericyte ECM suggesting that ECM produced by pericytes alone is not 
sufficient to support brain endothelial cell cultures. However, the de-cellularized ECM 
used in these experiments were derived from animal sources and it cannot be excluded 
that ECM from human sources would give a different result. The BM is a complex 
mixture of ECM from several cell sources and synergistic effects may be at play in the 
BM that are not accurately modelled using ECM from individual cell types. 
Consequently, the BM is highly important for normal BBB formation and function, 
but it remains unclear exactly how individual components contribute.  
 The blood-brain barrier and disease 
This thesis focuses on modelling of the healthy BBB. However, to appreciate possible 
future applications for iPSC-derived BBB models it is helpful to understand how the 
BBB is linked to disease. The BBB is of major clinical relevance as dysfunction of the 
BBB is observed in many neurological diseases, and the efficacy of drugs designed to 
treat neurological disorders is often limited by their inability to cross the BBB. BBB 
disruption is observed in many pathological conditions such as, stroke, multiple 
sclerosis (MS), human immunodeficiency virus (HIV) encephalitis, and Alzheimer’s 
disease (AD) (12), both as a cause of disease and as a symptom. BBB disruption refers 
to a decrease in the tightness of the barrier, resulting in less controlled transport across 
the barrier and higher permeability from the blood into the CNS. The connection 
between BBB permeability and AD is of increasing interest as the BBB is suggested 
to play a role in the accumulation of the AD hallmark amyloid β (Aβ) peptides. It has 
been hypothesized that a deficiency in the efflux of Aβ from the CNS contributes to 
accumulation and toxicity (54). This has also been shown in mouse models with 
mutations known to cause age-dependent Aβ accumulation and cognitive impairment 
(55). Efflux of Aβ is suggested to be mediated by the low-density lipoprotein receptor-
related protein 1 (LRP-1). In a mouse model, where LRP-1 was knocked down by 
antisense, brain Aβ levels increased by 40% and cognitive function declined. In 
addition, efflux of Aβ1-42 was more significantly lost than efflux of Aβ1-40, favouring 
retention of the more toxic form with aging (55). There is an increased uptake of Aβ 
into pericytes in AD and Aβ overload could explain the loss of pericytes seen in AD. 
Mouse models suggest that pericyte loss influences disease progression in AD by 
diminishing clearance of Aβ (56).  
Another example of a neurological disease with prominent BBB contributions is MS 
(57). MS is initiated by activation of myelin autoreactive T-cells that drive 
In vitro models of the blood-brain barrier using iPSC-derived cells 
11 
inflammatory response against myelin antigens in the CNS. In response to the 
inflammation, several pathways leading to loss of BBB tightness are activated, for 
example metalloproteases degrading the ECM and basement membrane. As BBB 
integrity is compromised, T-cells infiltrate the CNS and there is activation of 
macrophages and microglia. This collectively leads to demyelination, plaque 
formation, and ultimately neurodegeneration. Clearly, the BBB plays a major role in 
several diseases and consequently therapeutic targeting of the BBB is likely to 
increase.  
 The blood-brain barrier in drug discovery  
Diseases of the CNS are affecting an increasing number of individuals worldwide as 
the populations of most countries are aging. Furthermore, for many common diseases, 
such as neurodegenerative disorders, autism spectrum disorders and schizophrenia, 
there are no treatments affecting the disease and only few and inadequate options for 
treating the symptoms (58). The unmet medical need in neurological disorders is 
significant. A contributing factor is the many challenges in drug development of CNS 
active drugs. It has been estimated that almost all large molecule therapeutics and the 
majority of all small molecule drugs fail to penetrate the BBB (59). At the same time, 
major pharmaceutical companies are decreasing their investment in neuroscience 
research compared to other therapeutic areas (58). One plausible reason for the 
decrease in investment is the disproportionate failure rate in later stage clinical trials 
for CNS-targeting drugs compared to non-CNS-targeting drugs (60). Major challenges 
in CNS drug discovery include the multifactorial nature of many CNS diseases, 
difficulties in modelling the complexity of the CNS in vitro, and predicting BBB 
permeability. Consequently, there is a need for reliable models of the human BBB with 
high precision predictions of BBB permeability of novel drug molecules.    
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2 PERMEABILITY OF THE BLOOD-BRAIN 
BARRIER 
Controlled movement across the BBB involves restriction and facilitated transport of 
essential substances to supply nutrients. Transport into the CNS occurs through 
paracellular transport, transcellular diffusion, carrier-mediated-transport (CMT), 
receptor-mediated-transcytosis (RMT) and transcytosis (Figure 3). In addition, ATP-
dependent efflux transporters and ion pumps are active at the BBB. Small hydrophilic 
molecules may pass through the paracellular route; however, due to the high density 
of TJs in brain endothelial cells, this transport route is very restricted. Oxygen and 
carbon dioxide freely diffuse across the endothelial cell membrane in transcellular 
transport. Similarly, small lipophilic molecules, such as ethanol, can diffuse across.  
Figure 3. Transport across the blood-brain barrier. Small molecules such as oxygen 
and carbon dioxide can diffuse across the endothelial cell membrane in transcellular 
diffusion. Selective mediated transport occurs via receptor-mediated-transcytosis 
(RMT) or carrier-mediated-transport (CMT). In RMT the transported substance 
binds to a receptor which is subsequently internalized in a vesicle, transported 
across the cytosol and released on the other side of the cell by fusion of the vesicle 
with the membrane. CMT-specific transporters allow substances to pass through the 
cell down their concentration gradient. Diffusion in the paracellular space is very 
restricted at the BBB due to the high density of tight junctions, however, some 
molecules can still pass the barrier via paracellular diffusion. Transcytosis occurs 
via endocytosis, transport across the cell and exocytosis similar to RMT but without 
depending on receptors to bind the transported molecules. Efflux transport is 
polarized and occurs through pumping of substances from the cytosol back into the 
blood.  
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Larger molecules and nutrients such as glucose and amino acids rely on CMT or RMT. 
Moreover, the BBB is polarized, which means that the blood-facing side and the brain-
facing side of the endothelial cells have different compositions of transporters. The TJs 
between the endothelial cells function as boundaries restricting diffusion of 
transporters between the blood and the brain sides of the endothelial cells, maintaining 
the polarization of transporters.  
 Inter-cellular junctions  
Inter-cellular junctions between the endothelial cells at the BBB are made up of TJs 
and adherens junctions (AJs), in addition cluster of differentiation 31 (CD31) protein 
is highly expressed and its connections contribute to cell-cell adhesion (Figure 4) (61, 
62). Very constricted TJs are a hallmark of the BBB and limit the permeability of polar 
solutes in the paracellular space. AJs connect the cells through transmembrane 
cadherins, which reach from the cytoplasm to the extra-cellular space between the 
cells. Cadherins are linked to the cytoskeleton by the scaffolding proteins alpha-, beta- 
and gamma catenin. In brain endothelial cells, VE-cadherin is the most prevalent 
cadherin with only low levels of E and N-cadherin (62). The composition of TJs is 
more complex; transmembrane proteins; occludins, claudins and junctional adhesion 
molecules (JAMs) span the junctions between the cells. Occludins and claudins are 
linked to the cytoplasmic scaffolding proteins zonula occludens-1, 2 and 3 (ZO-1, ZO-
2, ZO-3). The claudin family is large and diverse, with more than 20 known subtypes 
(63). Claudin-5 is commonly identified as the most abundant claudin in brain 
endothelial cells (62), and both claudin-5 and claudin-3 have been shown to localize 
at TJs in the brain endothelium (64). WNT-signalling has been suggested to play an 
important role in stabilizing TJs and enhancing barrier properties, at least partly, 
through the regulation of claudin-3 (65, 66). The TJs are responsible for restricting the 
permeability of soluble molecules and ions, which gives rise to the high electrical 
resistance often used to characterize highly impermeable cell layers. In addition to 
anchoring the claudins and occludins to the cytoskeleton, ZO-1, ZO-2 and ZO-3 
function as regulatory elements by interacting with cytoplasmic proteins, signalling 
molecules and transcriptional regulators (67). Occludin expression is higher in brain 
endothelial cells than in peripheral endothelial cells and occludin expression levels 
have been shown to correlate with barrier tightness (2, 68, 69). The importance of 
occludin in the brain vasculature is further reinforced by reports of rare mutations in 
the occludin gene causing a disorder with severe malformations in cortical 
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development (70). TJ-associated proteins play an important part in creating the unique 
phenotype of brain endothelial cells and are frequently used to identify and visualize 
brain endothelial cells.  
 
Figure 4. Inter cellular junctions. Tight junctions contain occludins, claudins and 
JAMs which span the paracellular space. These are linked to the cytoskeleton via 
zonula occludes. Adherens junctions contain cadherins which span the paracellular 
space and are linked in the cytoskeleton via catenins. In addition, CD31 contributes 
to intercellular connections.  
 Transport proteins 
Brain endothelial cells control the ability of molecules and ions to diffuse from the 
blood into the brain. To supply the brain with required energy and nutrients, specific 
proteins at the BBB facilitate the transport (Figure 3). Selective mediated transport 
occurs through either CMT or RMT. CMT enables molecules such as carbohydrates, 
amino acids and vitamins to be transported down their concentration gradient through 
membrane carrier proteins. Examples of CMT include the solute carrier (SLC) 
transporters and the amino acid transporters (LATs). The energy supply to the brain is 
facilitated in this manner; the SLC transporter Glut-1 transports glucose down its 
concentration gradient from the blood into the CNS (71). In addition to Glut-1, the 
SLC transporter family contains numerous other transporters essential to the BBB, 
such as nucleoside and peptide transporters. RMT mediates transport of proteins and 
peptides through the binding of these to specific receptors. The receptors are 
subsequently internalized with the protein or peptide attached, shuttled across the 
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cytoplasm and released on the other side. RMT is responsible for the transport of 
nutrients and hormones such as iron, leptin and insulin across the BBB. Clathrin and 
caveolin mediate the formation of vesicles for RMT and non-receptor-mediated 
vesicular transport (72). Reduced caveolin-mediated transport has been identified as a 
differential factor between brain endothelial cells and peripheral endothelial cells. 
Furthermore, increased caveolin vesicle transport has been implicated as a contributing 
factor to barrier leakage (32, 73). As caveolin, but not clathrin, has been identified as 
a differential factor in BBB permeability, caveolin expression level is commonly 
investigated as an indicator of vesicular trafficking.  
 Efflux transporters 
The efflux transporter system works as a second security mechanism in the control of 
BBB permeability. Some substances may be able to diffuse across the cell membrane 
or are able to pass into the cell through CMT. However, they will have substantially 
reduced permeability into the CNS if they are recognized by the efflux transporters. 
Substrates of efflux transporters are efficiently shuttled back into the blood. Efflux 
transporters are ATP-binding cassette (ABC) transporters, they hydrolyse ATP to 
provide energy for transport of substances across the blood-side endothelial 
membrane. The three main efflux transporters are P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP) and multidrug resistance proteins (MRPs) (18). Efflux 
transporters have a broad substrate range, particularly P-gp, and are responsible for the 
low permeability into the CNS of many endogenous and exogenous molecules 
circulating in the blood. This protects the CNS from substances such as xenobiotics, 
pesticides and drugs, that could be harmful to the brain. Chemical properties of many 
drug molecules allow them to diffuse across cell membranes, however, they are also 
common substrates for efflux transporters, reducing their transport across the BBB 
(74).  
Assessing BBB permeability of novel drug candidates is of high importance, both for 
drugs targeting the CNS and other organs. For drugs targeting the CNS, there is a need 
to assess if penetration of the BBB is sufficient for the drug to be active and reach its 
target in the CNS. For example, many anti-cancer agents have very limited effects on 
cancers of the CNS due to low penetration of the BBB (75). On the contrary, a drug 
with a target outside of the CNS should preferably not enter the CNS as that may cause 
additional side effects. For example, the beta-blocker propranolol has been shown to 
readily cross the BBB and generate side effects, such as hallucinations, nightmares and 
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sleep disturbance, at a higher incidence than other beta-blockers with lower BBB 
permeability (76). Furthermore, it is important to evaluate drug-drug interactions, 
which can cause one drug to affect the clearance of another drug. One common way 
through which this occurs is when a drug affects efflux transporter activity. 
Interactions between drugs need to be carefully evaluated in drug discovery, and 
guidelines for how to perform these evaluations have been suggested by the US Food 
and Drug Administration (FDA). One of the key recommendations for evaluating drug-
drug interaction is to investigate if the drug has interactions with efflux transporter 
proteins P-gp and BCRP. The expression levels of BCRP and P-gp are substantially 
higher than expression of MRPs in brain endothelial cells (62). Hence, evaluation of 
efflux activity in the models developed in this thesis has focused on P-gp and BCRP. 
Clinically significant interactions with P-gp and BCRP have been reported for several 
drugs. For example, digoxin, which is used to treat various heart conditions, has been 
shown to interact with P-gp and is often co-administered with other P-gp interacting 
substances. Upon co-administration the availability of digoxin changes to correspond 
to a higher intake, which results in increased risk of over-dosing and generating side 
effects (77). Furthermore, at the BBB, common antidepressants such as selective 
serotonin re-uptake inhibitors, have been suggested to reduce the activity of P-gp, 
hence reducing its capacity to act as a protector of the CNS. Consequently, efflux 
transporter interaction studies are highly important in predicting BBB permeability and 
side effects of novel drug candidates.  
 Modulating blood-brain barrier transport for 
therapeutic purposes 
Entry into the CNS is a major challenge for many novel drug substances and one of 
the major hurdles in drug development for neurological disorders. Studies of how 
pathogens enter the CNS have revealed that interaction with surface proteins on the 
brain endothelial cells facilitate the process. For example, E. coli interacts with a 
glycoprotein on the brain endothelial cell surface, which facilitates its penetration of 
the BBB (78). This observation provoked ideas of adopting similar strategies for drug 
delivery. Several approaches to increase the permeability of drugs to the CNS are under 
investigation. Current strategies include transient opening of the BBB and using drug 
carriers or ligands that facilitate penetration (79, 80). For example, cancer drugs have 
been linked to amino acid sequences, recognized by the RMT system, to increase their 
BBB permeability (79). Furthermore, exploiting the RMT system can be used to target 
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specific regions of the brain with high expression of certain receptors. Other strategies 
have focused on reducing the activity of efflux transporters, specific inhibitors, such 
as elacridar and tariquidar, have been developed. Clinical trials to increase CNS 
availability of efflux transporter substrates using these inhibitors are ongoing (81). 
Modulating BBB permeability may be beneficial in increasing permeability of some 
drugs to the CNS, however, changing the general permeability of the BBB may have 
very severe side effects. Selective modulation of BBB permeability is preferable but 
clearly more difficult to accomplish.  
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3 iPSC-DERIVED CELLS FOR BLOOD-
BRAIN BARRIER MODELING  
Induced pluripotent stem cells (iPSC) are somatic cells reprogrammed to a pluripotent 
state using overexpression of defined transcription factors (82) (Figure 5). iPSCs are 
similar to embryonic stem cells (ESC) and can be differentiated to most cell types of 
the human body. iPSCs do not suffer from the same ethical obstacles as ESCs because 
they can be generated from cells obtained from an adult individual. The generation of 
iPSCs from adult cells allows for a number of new applications. Some cell types, such 
as neural cells and brain endothelial cells, are difficult to study in vitro due to the 
challenges in obtaining these cells from healthy individuals.  
Figure 5. Induced pluripotent stem cells are reprogrammed adult human cells from 
patients or healthy individuals. Once reprogrammed to an early development stage 
induced pluripotent stem cells can self-renew and be differentiated into most cell 
types of the human body.  
The iPSC technology provides great possibilities to generate large amounts of these 
cell types for in vitro studies without invasive sampling of healthy humans or use of 
animals for research purposes. Furthermore, iPSCs can be generated from patients to 
provide patient-specific cell lines, which can be used to produce and regenerate 
damaged tissues. iPSCs have a high proliferation capacity making them suitable for 
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large scale production of cells as well as genetic manipulation. To unleash the potential 
of iPSCs, robust and reliable protocols for differentiation are required. The 
development of differentiation protocols for directing iPSCs to a specific cell type 
generally relies on recreating the signalling processes that govern the development of 
the desired cell type during embryogenesis. 
 iPSC-derived endothelial cells 
Among well-defined signalling pathways, bone morphogenetic protein (BMP), FGF, 
and VEGF-signalling are most commonly modified for endothelial differentiation 
(83). The BMP family modulates early vascular development via the downstream 
SMAD family proteins, as demonstrated by studies in human embryonic stem cells 
(84). Treating stem cells with BMP early in the differentiation process has been shown 
to significantly induced endothelial differentiation (85). Notably, the VEGF family 
members were among the first secreted molecules observed to be specific to 
endothelial differentiation. VEGF receptors that are specific to the endothelial lineage, 
contribute to endothelial differentiation (86). This suggests that VEGF is not an early 
endothelial signalling cue but rather a later specification factor.  
The brain endothelial cells have different properties than the peripheral endothelial 
cells. Hence, the differentiation of brain endothelial cells from iPSCs may require 
specialized protocols different from those used to derive peripheral endothelial cells. 
In 2012, Lippman et al. published a protocol for differentiation of iPSCs to brain 
endothelial cells (87). During the years after 2012 several improvements of the 
protocol have been proposed, including the addition of retinoic acid (RA) (88), 
optimizing of seeding density (89) and use of more defined medium components (90-
92). The protocol relies on spontaneous co-differentiation of endothelial cells with 
neural cells and subsequent purification of the endothelial cells by passage on-to 
collagen/fibronectin in an endothelial cell medium containing FGF and RA. 
Particularly the RA treatment at the end of the differentiation has proven important for 
the cells to develop a mature BBB phenotype, with high tightness and increased 
expression of several TJ proteins and transporters (88, 91). Endothelial cells generated 
with this protocol display high TEER 500-4000Ohm x cm2, low permeability and 
expression of claudin-5, occludin, ZO-1, CD31, VE-cadherin and Glut-1 (88, 90, 93). 
Most recently, fully defined versions of this protocol that eliminate the use of serum 
have been proposed. These protocols give similar results as the original versions and 
rely on sequentially activating WNT- and RA-signalling, or spontaneous 
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differentiation followed by RA-signalling (91, 92). Other protocols for derivation of 
brain endothelial cells have been proposed, but without successful adoption in the iPSC 
BBB community. A proprietary method for deriving brain endothelial cells has been 
used in an investigation of apoE4 mediated endothelial cell toxicity, and more recently 
in a self-organizing microphysiological model (94, 95). Other protocols have used 
directed differentiation by sequential BMP and VEGF treatment to initiate 
differentiation to endothelial cells. Although these cells displayed upregulation of 
brain endothelial cell markers, they did not form tight monolayers and showed TEER 
values of approximately 50Ohm x cm2 (53, 96). The protocol developed by Lippmann 
et al., and subsequent optimizations of it, remains the most widely used methods for 
derivation of brain endothelial cells from iPSCs for in vitro BBB models. 
 iPSC-derived pericytes 
The development of differentiation protocols for pericytes has been hampered by the 
lack of detailed knowledge of the pericyte characteristics. Pericyte marker proteins, 
functional characteristics and even their origin have been debated. Before brain 
pericyte-specific protocols were developed, pericytes were mainly differentiated 
through mesodermal intermediates. Differentiation of the pericytes used in this thesis 
was performed before brain-specific pericyte differentiation protocols were developed. 
As such, the pericyte differentiation approach used in this thesis depends on 
mesodermal induction and further differentiation of sorted cells that lack CD31 
expression (97). Mesodermal differentiation was induced through activating TGF-β 
signalling by BMP4 and Activin, activation of WNT signalling and VEGF treatment, 
subsequent vascular specification through inhibition of TGF-β-signalling and 
continued VEGF treatment. After sorting of CD31-positive cells, the CD31-negative 
cells were further differentiated to pericytes by treatment with FBS, PDGFβ and TGF-
β. These pericytes were characterized through expression of caldesmon, SM22 and 
smooth muscle actin. Recently, an in-depth analysis of the cell types in the brain 
vasculature has provided new insight into the brain pericyte phenotype, and new 
markers that differentiate brain pericytes from peripheral pericytes were proposed, 
such as a higher abundance of SLC, ABC and ATP transporters (62). Brain pericytes 
have been shown to develop from neural crest stem cells (31), and recently a protocol 
for derivation of brain pericytes from iPSCs via neural crest stem cells was published 
(98). Initiation of neural crest differentiation was performed by WNT activation and 
TGF-β inhibition, neural crest stem cells were enriched through sorting, and pericytes 
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were generated through serum treatment. However, pericyte differentiation through 
both neural crest stem cells and mesodermal intermediates has given similar results 
(99). Mesodermal pericytes were derived via mesodermal induction and subsequent 
pericyte differentiation through culture in a proprietary medium promoting pericyte 
growth. Neural crest pericytes were derived through activation of WNT to derive 
neural crest cells and subsequent culture in the same pericyte growth medium. 
Development of well-defined differentiation protocols to derive brain pericytes from 
iPSCs is still in its initial stages. However, recent developments in generating brain-
specific pericytes hold great promise for their use in iPSC-derived BBB models. iPSC-
derived brain pericytes have been shown to reduce permeability of iPSC-derived brain 
endothelial cells at similar levels as induction by astrocytes and neurons (98). Since 
the role of pericytes may be primarily structural it is possible that Transwell BBB 
models benefit less from pericyte cocultures than microfluidic models where 
endothelial cells form vessel-like structures.  
 iPSC-derived astrocytes 
There are several published protocols for astrocyte differentiation from iPSCs, and 
iPSC-derived astrocytes have been used to study many different aspects of astrocyte 
biology including inflammatory response (100-102), glutamate uptake (101, 103), 
apoE biology (104) and genome wide expression studies (100, 101). Indeed, iPSC-
derived astrocytes have proven to be a powerful tool for understanding human 
astrocyte biology in health and disease. Astrocyte development and maturation occurs 
late in the embryonic development and continues after birth (4). As such, mimicking 
the in vivo astrocyte development is a very lengthy process, often spanning several 
months. Many protocols for astrocyte differentiation rely on long-term culture of 
neural stem cells in FGF and epidermal growth factor (EGF) and/or serum (105, 106). 
iPSC-derived astrocytes are commonly characterized by their expression of GFAP, 
CD44, EAAT1/2, S100B, and vimentin, and their ability to perform astrocyte specific 
tasks, such as glutamate uptake and inflammatory response to treatment with 
inflammation regulators (103, 106). Long-term differentiation protocols often require 
repeated passaging, selecting the proliferating population, which is likely to contribute 
to the long differentiation time as maturation of astrocytes generally reduces 
proliferation. There have been numerous efforts to shorten the differentiation time 
required for astrocyte development, for example, through remodelling of the chromatin 
structure (107) and using genetic techniques to overexpress transcription factors SOX9 
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and NF1A that govern the gliogenic switch in which neural stem cells switch from 
neurogenesis to gliogenesis (108). 
In this thesis, neural stem cells were derived using spontaneous differentiation and 
manual isolation of neural rosette forming cells (109). These were subsequently 
cultured in FGF and EGF and maintained as long-term neuroepithelial stem cells (lt-
NES) expressing the neural stem cell markers SOX1, SOX2 and Nestin. The protocol 
used to derive astrocytes from lt-NES is a slightly modified version of the protocol 
first published by Shaltouki et al. (103). It relies on 4 weeks culture of neural stem 
cells in FGF, heregulin, insulin-like growth factor 1 (IGF1) and activin A to drive 
astrocyte differentiation. It is still unclear exactly how these factors drive astrocyte 
differentiation, however, heregulin has been shown to play a particularly important 
role. Heregulin is a splice variant of neuregulin. It interacts with the EGF family of 
receptors and is able to induce astrocyte differentiation (103). Even with recent efforts 
to shorten protocols for astrocyte differentiation the process is still labour-intensive 
and long. Furthermore, the understanding of heterogeneity in human astrocytes is 
increasing and there is a growing interest in generating subtype-specific astrocytes 
from iPSCs. Both major astrocytic subtypes, protoplasmic and fibrous astrocytes, are 
in contact with the blood vessels in vivo (20). However, it remains unknown if 
astrocyte subtype influences the effects that astrocytes have on the brain vasculature 
and the BBB. 
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4 BLOOD-BRAIN BARRIER MODELS  
Models of the BBB serve as important tools in drug development and support 
evaluation of chemical properties and brain penetrating capacities of novel drug 
molecules. Regardless if the brain is the intended target or not, it is central to 
understand the permeability of a drug candidate into the CNS. Although many drug 
candidates appear promising in animal models, as many as 80% of them later fail in 
clinical trials (110). This clearly demonstrates the need for better pre-clinical models 
with higher translatability to the human in vivo situation. At the same time, large 
efforts are being made to reduce the use of animal testing in research. The three Rs 
ethical principle to reduce, replace and refine animal-based science is widely accepted 
and implemented throughout the research community. In many countries, the three Rs 
principle is explicit legislation. Human cell-based models are important alternatives to 
in vivo animal models and models using animal cells.  
Current models of the BBB span from in vivo animal models to more complex 
cocultures of several primary cell types and in silico modelling (111, 112). In vivo 
animal models, using techniques such as brain perfusion, are considered some of the 
most accurate ways of determining BBB penetration. However, these techniques 
require animals to be subject to research, are time consuming, expensive and have low 
throughput, compared to cellular models (111). A wide range of cellular models of the 
BBB have been described, including primary cells and cell lines from both human and 
animal origin. Primary cells from animals have proven to have suitable barrier integrity 
and relatively low permeability (112, 113), but disadvantages linked to the use of 
animal cells include resource demanding isolation procedures, batch-to-batch 
variability and incompatibility with reducing the use of animals for research. An 
important aspect of BBB modelling using animal cells is the differences between the 
human BBB and the BBB in other species. For example, there is evidence of species 
differences in the expression of BBB transporters, including the important efflux 
transporter P-gp, and in permeability of P-gp substrates (17, 18). By using 
immortalized cell lines from both human and animal origin, issues with reproducibility 
and batch variability can be circumvented. However, many of the immortalized brain 
endothelial cell lines available fail to form tight barriers with low permeability, which 
questions their usability. 
Availability of primary human brain cells is very limited, and samples are typically 
residual tissue from patient biopsies or post mortem brains. In addition, isolated 
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primary brain endothelial cells rapidly lose their BBB properties when cultured in vitro 
(2). Considering this loss of functionality in vitro, it is plausible that the BBB 
properties are not intrinsic to the brain endothelial cells but rather depend on the 
specific microenvironment that all components of the NVU create together. This 
suggests that a more complex model with coculture of multiple cell types is needed to 
recapitulate important functions of the BBB. Several coculture models have been 
described that demonstrate improved barrier properties compared to endothelial cells 
alone. There is a need for models that recapitulate the combined barrier functions of 
the BBB. A reproducible model from a continuous human cell source would increase 
the possibility of the model to be used in high-throughput screening experiments.  
A recent review identified five groups of criteria for benchmarking in vitro BBB 
models; structure (ultrastructure, wall shear stress, geometry), microenvironment 
(basement membrane and extracellular matrix), barrier function (TEER, permeability, 
efflux transport), cell function (expression of BBB markers, turnover), and coculture 
with other cell types (astrocytes and pericytes) (114). Historically, in vitro BBB models 
have used static two-dimensional (2D) cultures in Transwell plates, but recently 
perfused three-dimensional (3D) models have gained increasing interest (Figure 6). 2D 
static models have been very useful in providing new understanding of mechanisms of 
transport across the BBB and are still widely used to assess CNS transport in drug 
discovery processes. In 3D models the structure of the brain vasculature can be more 
accurately modelled and flow can be added to introduce shear stress, which more 
closely recapitulates the in vivo conditions. Even though most of our knowledge about 
BBB in vitro models come from static systems, shear stress arising from flow is 
thought to regulate several BBB specific properties, for example permeability, 
metabolism and expression of transporters (115). In an in vitro vessel with cylindrical 
geometry, there are relatively few cells that form tight interactions with each other 
around the vessel. This limits the motility of the cells more than in the 2D sheet of cells 
present in the Transwell models, and more accurately reflects the in vivo conditions.  
The basement membrane generates a specific microenvironment for the brain 
endothelial cells and its composition has been shown to effect BBB specificity of 
endothelial cells (36, 43, 44, 53). ECM proteins, such as collagen 1, are widely used 
in in vitro models but are not present at the healthy human BBB. Consequently, in vitro 
models need to provide a mix of ECM proteins carefully selected based on the 
composition of the in vivo BM. An alternative approach for creating a suitable ECM 
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would be to coculture brain endothelial cells with astrocytes and pericytes, which 
secrete many of the specific BM proteins that endothelial cells rely on in vitro.  
 
Figure 6. Schematic of common 2D and 3D monoculture and coculture BBB models. In 
2D Transwell cultures, endothelial cells are seeded on a porous membrane hanging 
inside a culture well. In coculture Transwell models, other NVU cell types can be added 
to the bottom of the membrane and/or to the bottom of the well. In 3D microphysiological 
systems (MPS), endothelial cells can be seeded in cylindrical hollow channels. Systems 
can contain single or multiple channels separated by porous membranes. In multiple 
channel systems, one channel can be used to culture the endothelial cell tube, and an 
adjacent tube can be used to culture other NVU cell types.  
 Characterization of in vitro BBB models 
Expression and localization of endothelial cell marker proteins are frequently used to 
characterize BBB models. Specifically, the expression of TJ proteins, such as occludin, 
claudin-5 and ZO-1, are used to verify that endothelial cells form TJs. TJs between 
brain endothelial cells create a physical barrier, which reduces permeability and 
Delsing, Louise 
28 
sustains polarization of transport proteins. Furthermore, the tightness of the barrier 
needs to be sufficient in order for any measurement of efflux activity to be meaningful. 
If the endothelial cells express efflux proteins but do not physically restrict the 
paracellular space, which is the case with many primary cell models, it is difficult to 
verify the activity of the efflux transporters. TEER measurements are the most 
common way of assessing how well the cells limit the transport in the paracellular 
space. High TEER represents a low paracellular transport and a tight monolayer. TEER 
measures the conductance of the cell membranes, a measurement that is relatively 
straightforward to perform in 2D Transwell cultures but can be very difficult to 
perform in microfluidic 3D models. TEER measurements are not feasible in vivo but 
in vivo TEER values have been estimated to be above 1000Ohm x cm2. Even though 
systems with physiological TEER will have negligible paracellular transport, the 
permeability across a monolayer is not linearly correlated with the TEER. In addition, 
TEER is affected by other parameters such as the composition of solutes in the 
medium, temperature and handling of the equipment during the measurement. Hence, 
permeability measurements using small molecular tracers should be performed in 
addition to TEER measurements. Fluorescent tracers provide an opportunity to follow 
permeability in real time and assessment of permeability with a fast and easy plate 
reader analysis. Small fluorescent substances are commonly used for such analyses, 
for example, fluorescent dextrans of different sizes, sodium fluorescein and Lucifer 
yellow.  
Evaluations of expression and functionality of efflux transporters are important to 
understand the translatability of BBB models when determining entry of novel 
therapeutics into the CNS. The two most studied transporters are P-gp and BCRP. In 
2D Transwell systems where bi-directional permeability measurements are possible, 
efflux ratio is often used to determine if a substance is affected by efflux transporter 
activity. As efflux transporter location is polarized and mostly located in the apical 
(blood facing) membrane the transport of an efflux transporter substrate is lower in the 
apical to basolateral direction (blood to brain) than in the basolateral to the apical (brain 
to blood) direction. The efflux ratio is the ratio between the apical to basolateral and 
the basolateral to the apical transport. Consequently, the efflux ratio of a substance 
with equal permeability in both directions not affected by efflux is 1, while substances 
affected by efflux typically has efflux ratios of 2-10. Generally, a substance with efflux 
ratio greater than 2 is considered an efflux transporter substrate. Investigation of efflux 
transporter functionality can also rely on analysing the permeability of known efflux 
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transporter substrates with and without inhibition of the efflux transporters. For 
example, rhodamine 123 is a known substrate of P-gp and its permeability can be 
monitored with or without the addition of the P-gp inhibitor verapamil. In 3D dynamic 
systems bi-directional transport measurements are often difficult to perform, hence the 
investigation of efflux functionality usually relies on permeability studies of known 
substrates with and without inhibition of the efflux transporters.  
Astrocyte cocultures have shown to improve barrier properties in many in vitro BBB 
models (93, 96, 116). These models use non-contact cocultures, suggesting that the 
astrocyte contribution occurs mainly via soluble factors. However, in vivo, astrocytes 
have a significant structural contribution to the barrier with astrocytic end-feet 
wrapping around the endothelial cells. Due to the difficulties in recreating the 
astrocyte-endothelial cell structural connections in vitro, the significance of the 
physical interaction of these two cell types remains elusive. Pericyte cocultures have 
similarly been reported to be beneficial to BBB models (98, 99, 117), and many of 
these have the pericytes in close proximity to the endothelial cells. Pericytes surround 
endothelial cells and help regulate capillary diameter and blood flow, which suggest 
that the contact between pericytes and endothelial cells is important. In addition, both 
pericytes and astrocytes contribute structural components of the BBB by secreting 
proteins that constitute the basement membrane.  
In summary, for improved translatability to the in vivo situation, a BBB model should 
adopt a 3D tubular morphology and the endothelial cells should be subjected to shear 
forces. Endothelial cells should express TJ markers and efflux proteins. The 
permeability across the endothelial cell layer should be low. BBB model can benefit 
from coculture with astrocytes and pericytes, however the intended use for the model 
ought to dictate what level of complexity is needed.  
 iPSC-derived blood-brain barrier models  
A model with iPSC-derived cell types could overcome the challenges with 
reproducibility and availability of human cells and would provide the possibility for 
an isogenic model with all cell types originating from the same human individual. In 
addition, using iPSC-derived cells would reduce the need for animals and animal 
derived tissues to be used. The establishment of an iPSC-derived BBB model requires 
robust and reliable differentiation protocols for derivation of several cell types of the 
CNS. As described above, differentiation protocols for endothelial cells, astrocytes and 
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more recently pericytes are available. Hence an iPSC-derived BBB model is feasible, 
and during recent years, there has been a rapid increase in iPSC-derived BBB models. 
The establishment of the brain endothelial cell differentiation protocol by the Shusta 
lab in 2012 (87) served as an accelerator for iPSC-derived BBB model work. Most of 
the published iPSC-derived BBB models used variations of that differentiation 
protocol. Several of these iPSC-derived BBB models have rapidly developed into tools 
for investigation of drug permeability studies (87, 116, 118-120), disease modelling 
(7, 99, 121-123) and modelling of BBB disruption (124-127). Both monoculture 
models of the BBB using only iPSC-derived endothelial cells and coculture models 
with endothelial cells and other cell types of the NVU have been established. Coculture 
models contained endothelial cells and different combinations of astrocytes, pericytes, 
neurons and neural stem cells (93, 98, 116, 128). iPSC-derived coculture models of the 
BBB formed monolayers with highly restricted permeability in the paracellular space. 
TEER values for coculture models have been reported to be higher than 6000Ohm x 
cm2 (128), however the variability in maximum TEER reported between iPSC-derived 
models is quite high and others have reported TEER values of ~1000-4000Ohm x cm2 
(91, 93, 116). Permeability of passively diffused soluble substances such as fluorescein 
have been reported to be in the range of ~1-5 x 10-7cm/s in iPSC-derived BBB models 
(90, 93). This was substantially lower than the permeability achieved in brain 
endothelial cell line cultures of ~12-15 x 10-6cm/s (129) and can be compared to in 
vivo measurements in rat of 2.7 x 10-6cm/s (130). Efflux by P-gp is commonly 
investigated and found to be active in iPSC-derived BBB models, however, the activity 
of P-gp was not affected by coculture (93, 116, 128). Across iPSC-derived BBB 
models coculture with astrocytes appears to increase the barrier restriction capacity of 
the endothelial cells. Results from pericyte cocultures are more conflicting, with some 
studies showing improved barrier restriction with coculture (88, 90, 98, 128) and other 
reporting no differences (116, 117). Interestingly, these conflicting results have been 
reported for both cocultures with iPSC-derived pericytes and primary pericytes. One 
of these studies demonstrated that even though pericyte coculture had no effect on 
endothelial cells under normal conditions, pericyte coculture had the ability to rescue 
barrier properties in stressed endothelial cells and allowed endothelial cells to maintain 
high TEER over longer culture time. This suggested that the pericyte contribution in 
in vitro BBB models was maintenance rather than induction (117). These discrepancies 
highlight the numerous factors contributing to variability in complex multicellular 
models, such as the iPSC-line background, culture conditions and assay conditions. 
Even though some differentiation protocols have proven to be highly robust and 
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transferrable between different labs and applications, variability is an issue when 
comparing models. This was exemplified in a study comparing the differentiation 
capacity of four different iPSC lines to isogenic BBB models including endothelial 
cells and astrocytes (131). Even though many iPSC-derived BBB models have been 
developed, characterized and used in different applications, several questions remain. 
To facilitate the use of iPSC-derived BBB models in disease modelling and drug 
discovery, the mechanism of BBB induction by coculturing cell types and the 
expression and functionality of more brain-specific transporters need to be thoroughly 
investigated. Furthermore, additional studies of drug permeability prediction are 
needed.  
 Microfluidic models 
Recently several microfluidic BBB models containing iPSC-derived endothelial cells 
have been reported (95, 117, 132-136). These models aim to recreate the 3D 
morphology of vessels and allow the cells to interact under more physiological 
conditions. In these models, the cells are subject to shear forces introduced by flow, 
similar to the in vivo conditions in brain blood vessels. The shear forces that affect the 
cells are determined by the vessel diameter, the viscosity of the flowing liquid and the 
flow rate. Human micro-vessels and shear stress have been studied in the eye where 
diameters ranged between 6 and 24µm. The shear stress was measured to be between 
2.8 and 95dyne/cm2, the calculated average shear stress was 15.4dyne/cm2 (137). 
These findings can be compared to measurements of vessel diameters in the human 
motor cortex where the perforating capillaries have a diameter ranging from 5 – 8µm, 
the arterioles have a diameter ranging from 10 – 15µm and the venules have a diameter 
ranging from 16 – 20µm (138). Brain post capillary venules are characterized by 
diameters of around 100μm, a relatively thick basement membrane, and a wall shear 
stress of 1–4dyne/cm2 (114, 138). Compared to the human in vivo brain vasculature, 
most BBB microphysiological systems (MPS) recreate an environment, which is 
similar to the vessel diameter and shear forces of post capillary venules. Similarly to 
the static models, the majority of iPSC-derived MPS models have used variants of the 
protocol proposed by Lippmann et al. (88) to derive brain endothelial cells and cultured 
them as monocultures or cocultures. Several coculture models used primary sources 
for pericytes and astrocytes (95, 132, 134). However, recently two fully iPSC-derived 
models have been reported, one using iPSC-derived pericytes (117) and one using 
iPSC-derived neural cells for coculture (133). iPSC-derived BBB models in MPS 
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formed tight barriers and showed low permeability, below 5x10-7cm/s for 10kDa 
dextran in both monoculture of brain endothelial cells (135, 139) and coculture models 
(95, 132, 133). Similarly to static 2D models, MPS BBB models showed active P-gp 
efflux (132, 135, 139) and improvements in barrier phenotype after coculture (133, 
134). 
Comparing 2D and 3D models to elucidate effects of more physiological culture 
conditions and addition of shear stress is challenging. Consequently, effects of 
introducing shear stress on iPSC-derived brain endothelial cells are not well studied. 
Evaluation of permeability between static and dynamic models will have inherent 
differences in physical prerequisites. Furthermore, elucidating what differences flow 
creates is difficult because medium volumes in many MPS are low and therefore flow 
is necessary to supply the cells with oxygen and nutrients. Hence, creating a static 
culture in these systems is often not possible and direct comparisons between static 
and dynamic conditions are not feasible. Despite these difficulties, comparisons of 
MPS cultures with and without shear stress have been reported (136, 139). It was 
concluded that introducing shear stress on iPSC-derived endothelial cells had other 
effects than introducing shear stress on primary endothelial cells. iPSC-derived 
endothelial cells subjected to shear stress had lower apoptosis, lower proliferation and 
lower cell mobility, however no change in TJ proteins were found, even though shear 
stress served to increase contact area between cells (136). Another recent study 
comparing iPSC-derived brain endothelial cells under shear stress and static conditions 
showed that iPSC-derived brain endothelial cells that were subject to flow had lower 
passive paracellular permeability but no difference in efflux transporter activity (139). 
However, expression levels of several tight junction and endothelial cell markers have 
been found to depend on the flow rate in a fully iPSC-derived model (133). Studies of 
primary brain endothelial cells revealed interesting effects of shear stress in culture. 
Under flow, these cells went from a mostly anaerobic metabolism producing lactate to 
a mixed aerobe and anaerobe metabolism producing both lactate, H2O and CO2 (115). 
There have been speculations that, as the BBB tightens more active and energy 
demanding transport is necessary and hence the endothelial cells make use of a more 
aerobic metabolism, which is more efficient in generating ATP. Another speculation 
was that the metabolism is dependent on blood flow and thus oxygen levels. When the 
blood flow is low and hence the oxygen availability is low, a more aerobic metabolism 
can be utilized. 
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In addition, MPS models have been suggested to be more compatible with permeability 
screening as continuous sampling is possible in dynamic systems. However, many 
MPS models require complex laboratory setups that are incompatible with high-
throughput screening. There is evidence that MPS may be useful for providing a 
physiologically more relevant culture environment for iPSC-derived BBB models. 
However, many questions remain regarding how adding flow and a 3D culture 
environment benefit iPSC-derived BBB models.  
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5 AIMS 
The thesis aims were to develop human iPSC-derived models of the BBB that display 
barrier phenotype and characterize these models in terms of brain endothelium-specific 
properties. The model development was based on investigations of mechanisms 
important for barrier formation in iPSC-derived endothelium and development of high-
quality cells to use in the model. The possibilities to use the model in drug discovery, 
and in determination of brain-penetrating capacity of drugs were specifically 
considered.  
The specific aims were: 
• To increase the knowledge of the molecular mechanisms behind the 
restricted permeability across iPSC-derived endothelial cells and to identify 
transcriptional changes that occur in iPSC-derived endothelial cells upon 
coculture with relevant cell types of the neurovascular unit. (Paper I) 
 
• To develop and identify high-quality astrocytic cells, and to evaluate the 
biological relevance and model diversity between astrocytic models. (Paper 
II) 
 
• To evaluate a xeno-free differentiation process of iPSCs to astrocytes, and 
subsequently evaluate the capacity of xeno-free-derived astrocytes to induce 
BBB properties in iPSC-derived endothelial cells. (Paper III)  
 
• To generate a biologically more relevant iPSC-derived BBB model and to 
improve compatibility with high-throughput substance permeability 
screening by developing a microphysiological dynamic model. (Paper IV) 
Delsing, Louise 
36 
  
In vitro models of the blood-brain barrier using iPSC-derived cells 
37 
6 METHODOLOGICAL CONSIDERATIONS 
The following section describes the reasoning behind method choices and discusses 
advantages and limitations of the methods used in this thesis. Detailed methods for 
specific experiments can be found in Paper I-IV.  
 Ethics 
Human iPSC lines C9 and C1 used in these studies were derived with written informed 
consent by the donors or their parents. Generation of iPSCs were reviewed and 
supported by regional ethical consent boards. R-iPSC1j were generated from BJ 
fibroblast (CRL-2522) purchased from ATCC, Manassas, Virginia, USA, in 
compliance with the ATCC materials transfer agreement. AF22 were generated 
from primary fibroblast purchased from Cell Applications Inc., San Diego, CA, 
USA and were used in compliance with vendor agreements. ChiPSC22 iPSC line 
were purchased from Takara Bio, Kusatsu, Japan and used in compliance with 
vendor agreements. SFC-SB-AD2-01 iPSC line were obtained through the Innovative 
Medicines Initiative Joint Undertaking StemBancc and used in compliance with user 
agreements. Primary brain endothelial cells (Cell Systems, Kirklans WA, USA), 
astrocytoma cell line CCF-STTG1 (ATCC, Manassas, VA, USA), human 
embryonic kidney cell line HEK293 (ATCC, Manassas, VA, USA), human brain 
astrocytes HBA (Neuromics, Edina, MN, USA), immortalized brain endothelial cell 
line CMEC/D3 (Merck, Kenilworth, NJ, USA), and iPSC-derived iCell Astrocytes 
(FUJIFILM Cellular Dynamics, Inc, Madison WI, USA) used are commercially 
available and used in compliance with vendor agreements.  
 Cells 
Even though iPSC lines generally are of high quality and exhibit the gold standard 
requirements for stem cells, there are inherent differences between cell lines. These 
differences have previously been investigated in isogenic BBB models and subtle 
variances in marker expression and maturation state were observed (131). Observed 
differences may depend on multiple factors, such as genetic makeup of the donor, the 
cell type and method that was used to derive the iPSCs, and under what culture 
conditions the iPSCs have been maintained. Due to the inherent differences between 
lines they may respond differently to differentiation, coculture or other treatments. 
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Thus, it is important to include several iPSC lines in the experiments to be able to draw 
general conclusions. In this work, the aim has been to include 2-3 lines per experiment. 
In some cases, one line has been used in parts of the analyses after sufficient 
verification that similar outcome for other lines is to be expected.  
 Differentiation of iPSC-derived endothelial cells 
Differentiation of iPSC-derived endothelial cells was evaluated using one protocol 
generating brain-specific endothelial cells through a differentiation process that 
includes spontaneous neuroectodermal coculture (88, 90) and one general endothelial 
cell differentiation protocol (97), in which cells are generated via mesenchymal 
induction. Most of the work was performed using cells derived with the brain-specific 
endothelial cell differentiation protocol. This protocol was first published in 2012 (87), 
modifications and improvements of the protocol have since then been implemented 
(88, 90). Until very recently this protocol was the only published brain endothelial cell 
differentiation protocol generating endothelial cells capable of forming tight 
monolayers. It has proven to be robust and has been successfully implemented with 
many different iPSC lines and labs for numerous applications. iPSC-derived 
endothelial cell characterization is based on both expression of endothelial cell markers 
and ability to form a restrictive barrier, further discussed below. 
 Differentiation and functional characterization 
of iPSC-derived astrocytes 
Differentiation of iPSC-derived astrocytes was performed using a modified version of 
a previously published protocol (103), which provides the possibility to generate 
astrocytes from neural progenitors within a month. Astrocytes are a very diverse cell 
type, and as such, finding a common marker to identify astrocytes has proven difficult. 
GFAP is commonly used as an astrocytic marker, but not all astrocytes in the human 
brain express GFAP (140), and GFAP expression is commonly recognized as a marker 
for reactive astrocytes (29). Preferably, expression of several astrocyte associated 
proteins, in combination with functional testing, should be used to characterize 
astrocytes. In these studies, glutamate uptake, inflammatory response and calcium 
signalling were used to evaluate important functionality of astrocytes. Glutamate 
uptake analysis was performed by measuring the decrease of glutamate in the culture 
over time using a colorimetric assay, with or without the addition of glutamate 
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transporter inhibitors. To avoid interference with the glutamate detection process, non-
substrate inhibitors were used. All glutamate uptake measurements were normalized 
to number of cells in each well through either nucleus counting or double stranded 
DNA content. Astrocytes are active in the immune response of the CNS and 
inflammatory response assays were performed by measuring secretion of cytokines 
indicating reactive activation with or without stimulation with the proinflammatory 
factors TNFα and IL-1β, known to be produced by microglia, leukocytes and 
astrocytes. Calcium signalling analysis was performed using a neutral calcium 
indicator that can cross the cell membrane. Once inside the cell, the indicator is cleaved 
by esterases activating its calcium-binding properties and rendering it charged, which 
prevents transport out of the cells. When calcium is released, it is bound by the 
indicator and increases its fluorescence. Calcium signalling was measured in response 
to ATP and glutamate and was compared to an injection control as changes in shear 
stress has been shown to influence calcium signalling.  
 Characterization of protein and mRNA 
expression 
Protein expression was analysed using immunocytochemistry (ICC) for intracellular 
proteins and enzyme-linked immunosorbent assay (ELISA) for secreted proteins. ICC 
provides the possibility to visualize the location and pattern of expression of the 
investigated protein that other methods, such as western blot, do not provide. When 
studying important structural components such as TJs it is helpful to be able to assess 
if TJ proteins locate to the cell junctions and if there are continuous TJs between cells, 
which is a requirement for permeability restriction across the cells. Expression analysis 
through qPCR is a useful tool to detect changes in expression of certain genes of 
interest. A change in mRNA may indicate that there are changes in protein expression, 
even if the relationship between mRNA and protein expression is not perfectly 
correlated. Equally important, a protein can be present in a cell without exhibiting its 
function. Hence, the characterization of cells should contain analysis on mRNA level, 
protein level and functional analysis. Complementary mRNA and ICC analyses are 
highly desirable, but not always feasible when quality antibodies to detect the protein 
of interest are not available. Developing specific antibodies against membrane proteins 
has been a long-standing challenge due to the difficulties in delivering enough protein 
in pure enough forms with intact tertiary structure to immunize. This can be a particular 
challenge when studying the BBB where many of the proteins and transporters of 
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interest are membrane-bound. qPCR analysis also comes with the need to carefully 
consider methods for normalization of samples. For experiments in this thesis three 
housekeeping genes were tested and the most stable one was selected using the 
NormFinder algorithm (141). Adding shear stress to a BBB model system has been 
shown to cause major shifts in fundamental processes such as metabolism and protein 
production (115), because of this five housekeeping genes were evaluated with 
NormFinder for experiments in Paper IV.  
 Barrier integrity assays 
Barrier integrity assays are performed using TEER and permeability analyses of 
fluorescent tool compounds and drug substances. TEER measures the conductance of 
the cell membranes: high TEER represents a low paracellular transport and a tight 
monolayer. TEER is a fast, easy and effective method of assessing tightness of a cell 
monolayer. However, it is important not to rely solely on TEER for permeability 
measurements as this method is quite variable and exact values can be problematic to 
compare between labs. A universal permeability measurement such as apparent 
permeability (Papp) is preferable when comparing models and hence both of these 
methods can be used together to get comprehensive information on permeability across 
a BBB model. Efflux transporters are an important aspect of permeability restriction 
across the BBB. In this work, efflux transporter analyses have focused on the efflux 
transporters P-gp and BCRP as they are both highly expressed in the BBB and have 
been found to limit the brain permeability of many drug substances. Analysis of efflux 
protein activity and polarization was performed through directional permeability 
analyses and permeability studies with and without inhibiting the efflux transporters. 
Fluorescence-based assays where the permeability of a fluorescent substrate is 
monitored provides significantly simpler analyses compared with other methods of 
determining substrate concentrations such as mass spectrometry or radiolabelling of 
substances. Even though these assays are generally very useful they have certain 
limitations. For example, any assay using a P-gp substrate to detect the interaction with 
P-gp of another substance will be limited by the affinity of the substrate to P-gp. It will 
be difficult to detect effects of substances with a lower affinity to P-gp than the chosen 
substrate. In addition, non-substrate inhibitors will be difficult to separate from 
substrates with high affinity having prolonged attachment to P-gp, which slows down 
its activity rate.  
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 RNA sequencing and pathway analysis 
RNA sequencing (RNAseq) is a powerful method for identifying and characterizing 
cell cultures by investigating the expression of all genes under certain conditions. It 
allows for analysis of the similarity and differences between samples and of larger 
groups of genes related to a specific functionality or a specific signalling pathway. An 
important limitation of the technique is that it gives cross-sectional data and does not 
capture dynamic changes. Signalling pathways regulated by genes identified as 
differentially expressed by RNAseq can be detected with pathway enrichment analysis. 
Such pathway enrichment analyses depend on lists of genes annotated in databases to 
belong to certain pathways. Overrepresentation of the members of such gene lists 
among the differentially expressed genes is then investigated. Even though signalling 
is a dynamic process, evaluating expression of most of the components of a signalling 
pathway can provide insight into differences between samples. However, experimental 
verification is still required. RNAseq experiments in this thesis examines bulk RNA, 
the collected RNA from a pool of cells. Another RNAseq method is single cell 
RNAseq, where data is collected for each cell separately. This kind of analysis would 
be interesting to perform in future analysis of iPSC-derived BBB model as it can 
provide further insight about heterogeneity within the cell population. However, it 
requires a more complex and time-consuming analysis compared to bulk RNAseq.  
 Microphysiological culture systems 
To create a more physiological culture setting for brain endothelial cells efforts are 
under way to adapt cultures to MPS. Most MPS use tubing and pumps to create a 
dynamic flow culture, which provides shear stress and flow that are unidirectional and 
adjustable. However, these systems require complicated laboratory setups that are very 
difficult to run in high-throughput. The Organoplate used in this thesis provides 40 
units within one 384 well plate creating a system which is suitable for automated high-
throughput screening, but has a bi-directional flow driven by gravity on a tilting 
platform. Thus, the Organoplate system provides a compromise in which a 
unidirectional flow system is sacrificed in favour of a system with bi-directional flow 
suitable for high-throughput screening. However, rat brain capillary endothelial cells 
in vivo experience flow fluctuations, extended stalls and even reversals of direction 
under physiological conditions (142). Even though the Organoplate clearly has the 
potential to be used in high-throughput screening, this has not yet been reported for 
any BBB models. The Organoplates’ parallel membrane free channels are suitable for 
Delsing, Louise 
42 
barrier integrity assays relevant specifically to the BBB, vasculature and renal models, 
which represent the majority of the developed models in this system. The Organoplate 
endothelial tube compartment is 400 x 220µm, when plates are perfused at a 7° angle 
the cells are subject to a shear stress of 1.2dyne/cm2, which is comparable to the shear 
stress in post capillary venule in the brain. Consequently, the Organoplate system is a 
feasible option for creating a perfused, 3D, high-throughput compatible iPSC-derived 
BBB model.  
 Statistical analysis 
Most of the statistical tests in this thesis were performed using an ANOVA or double-
sided Student’s t-test. Student’s t-tests are used to compare means of two groups e.g. 
coculture vs. monoculture, L2020 differentiation vs. LN521 differentiation or 
Transwell vs. MPS. In this work such comparisons were only made within iPSC lines. 
To perform multiple comparisons ANOVA was used and p-values were corrected for 
multiple comparisons using Tukey’s or Dunnett’s methods if all groups were compared 
to each other or if treatments were compared to a control, respectively.   
Experiments in this thesis generally rely on three independent replicates and three 
technical replicates for each analysis. Technical replicates are included to control for 
variability in the testing protocol. Cell culture data brings controversy with regards to 
what is considered a biological replicate and what is simply a technical replicate. In 
iPSC-derived models in this thesis, replicates represent different batches of 
differentiation. However, one could argue that since these cells all come from the same 
parent iPSC line using three differentiation batches are only technical replicates of the 
differentiation protocol. Hence multiple iPSC lines have been used as each iPSC line 
can be viewed as a biological replicate. The statistical comparisons were typically 
made within the same line and subsequent conclusions were made based on what 
trends were observed for all lines. Similar issues can be raised for immortalized cell 
lines, whether a new batch of frozen cells is a biological replicate or if a new isolation 
is needed to obtain a new biological replicate. For cell lines, such as the CMEC/D3 
used in this thesis, replicates come from individual cultures prepared separately but 
originating from the same stock. One possible solution to this problem would be to 
include several different brain endothelial cell lines. In this thesis, the brain endothelial 
cell line was used as a reference and was not the primary the focus of the work, hence 
only one line was included.  
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RNAseq data is not normally distributed; it has a negative binomial distribution. 
Transcript abundance is estimated by read counting, so the measured variable is 
discrete. In addition, RNAseq data is heteroscedastic, meaning that variance in 
expression depends on the mean. All of these features have to be considered in 
visualization and statistical testing of the data. RNAseq data was analysed using R and 
the DESeq2 package. To perform visualizations such as a principal component analysis 
(PCA), the data was normalized using the regularized log2 method to correct for 
heteroscedasticity and sequencing depth. Statistical analysis was performed with a 
generalized linear model and the Wald test was used for significance testing. 
Corrections for multiple comparisons were done using the Benjamini-Hochberg 
method. The threshold for false discovery rate was set to 5%. For visualization in bar 
plots, the data was normalized for sequencing depth and gene length using the 
fragments per kilobase million (FPKM) method for paired-end sequencing. Pathway 
analysis was performed with the DAVID tool using Fisher’s exact test to investigate if 
any pathways were enriched among the differentially expressed genes. The Benjamini-
Hochberg correction for multiple comparisons were used
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7 SUMMARY OF FINDINGS 
 Paper I: Barrier Properties and Transcriptome 
Expression in Human iPSC-Derived Models of 
the Blood-Brain Barrier 
There is a need for better in vitro models of the BBB as immortalized cell lines and 
primary brain endothelial cells have limited capacity to recreate barrier restriction 
when cultured in vitro. iPSC-derived brain endothelial cells have been shown to exhibit 
high barrier function in vitro. This work was designed to set up a fully iPSC-derived 
model of the BBB containing endothelial cells, pericytes, astrocytes and neurons that 
recapitulate barrier functions of the BBB in vitro. It investigated how different methods 
of deriving endothelial cells from iPSC affected their ability to serve as BBB models. 
Furthermore, the BBB specification of endothelial cells in coculture with other cell 
types of the NVU, was investigated. Both the functional changes in barrier restriction 
and the transcriptional changes induced by coculture were evaluated. Two published 
protocols for generation of endothelial cells were compared, one which generates an 
unspecified subtype of endothelial cells and another which generates brain-specific 
endothelial cells. The endothelial cells in monoculture and coculture with iPSC-
derived pericytes, astrocytes and neurons were then compared. The results showed that 
the brain endothelial cell-specific protocol generated a BBB model with highly 
selective permeability. These cells had markedly improved barrier properties 
compared with the cells derived using the other protocol, which generated unspecified 
endothelial cells. The brain-specific endothelial cells had high TEER and low passive 
permeability of fluorescein. Coculture of brain specific endothelial cells with iPSC-
derived astrocytes, pericytes and neurons improved barrier properties and the 
cocultured brain endothelial cells showed higher TEER and lower fluorescein 
permeability compared to the monocultured brain endothelial cells. Efflux 
transporters, such as P-gp and BCRP regulate the brain penetration of many drug 
molecules and the activity of these efflux transporters are very important for correct 
modelling of permeability, especially of drug-like substances, which often are small 
and able to diffuse across cell membranes. The brain-specific endothelial cells in 
monoculture and coculture showed active efflux by P-gp, while only the cocultured 
endothelial cells showed active efflux by BCRP. No activity of P-gp or BCRP, could 
be detected in the nonspecific endothelial cells in either monoculture or coculture. The 
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apparent permeabilities of six drug substances were tested and the brain specific 
coculture model could distinguish between CNS permeable and non-permeable 
substances. To understand molecular mechanisms behind the improvement seen in the 
coculture, the transcriptome of iPSC-derived endothelial cells in monoculture and 
coculture were compared. Coculture increased the expression of both junction-
associated mRNAs and brain specific transporter mRNAs. A pathway analysis 
revealed enrichment of changed genes in the WNT, TNF and Pi3K-Akt pathways. 
These data suggested that differentiation towards brain-specific endothelial cells is 
needed to obtain endothelial cells with the capacity to form a tight barrier in vitro. 
Furthermore, non-specific endothelial cells derived from iPSCs did not develop brain-
specific endothelial cell properties by coculture with NVU cell types. Our results 
suggested that the coculturing cell types exerted an influence on the brain endothelial 
cells through the WNT, TNF and Pi3K-Akt pathways, ultimately leading to a more 
highly restricted barrier in coculture. This work highlighted the plasticity of the iPSC-
derived brain endothelial cells and the ability of coculture with other cell types of the 
NVU to enhance their barrier phenotype.  
 Paper II: Human iPS-Derived Astroglia from a 
Stable Neural Precursor State Show Improved 
Functionality Compared with Conventional 
Astrocytic Models  
This work was aimed at developing iPSC-derived astrocytes and to evaluate their 
usefulness as an astrocyte model compared to conventional astrocytic models. Models 
were compared in terms of transcriptome, protein expression and functionality. 
Astrocytes were derived from lt-NES, a homogeneous and stable neural precursor, 
which provides shorter differentiation time compared to starting from iPSCs. In this 
work it was established that lt-NES can acquire gliogenic potency by expression of 
key gliogenic transcription factors SOX9 and NFIA. Astrocytes derived from NES 
(NES-astro) expressed many key glia marker proteins such as brain lipid-binding 
protein (BLBP), S100B, CD44, SLC1A3 and several astrocyte related mRNAs such 
as GFAP, aldehyde dehydrogenase 1 family member L1 (ALDH1L1) and aquaporin 4 
(AQP4). NES-astro were compared to primary human astrocytes (phaAstro), the 
astroglioma cell line CCF-STTG1 (CCF) and the commercially available iPSC-derived 
astrocytes (iCellAstro). In addition, the neural stem cell lt-NES and human embryonic 
kidney cell line (HEK) served as neural and non-neural controls respectively. 
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Transcription and protein expression analysis revealed large differences between the 
models. As there is no reliable marker or transcription identity that fully specifies 
astrocyte biology, several important functional properties were compared between the 
different models. Removal of excess glutamate in the synaptic cleft is a critical 
astrocytic function that ensures reliable synaptic signalling and prevents excitotoxicity 
in neurons. The glutamate uptake mainly occurs through the sodium dependent 
glutamate uptake transporters EAAT1 (SLC1A3) and EAAT2 (SLC1A2). NES-astro 
showed active glutamate uptake through SLC1A3 that was not observed in any of the 
other models. Another important function of astrocytes in vivo is to produce an 
inflammatory response. This capacity was assessed by stimulation with inflammatory 
cytokines and subsequent evaluation of the response by measuring secreted IL6 and 
IL8. Dose dependent inflammatory responses were detected in NES-Astro, these 
responses were significantly different from the response in NES. Inflammatory 
responses were detected in the other models as well, however the baseline IL6 and IL8 
levels were high in phaAstro, CCF and iCellAstro while no base line secretion was 
detected from NES-astro. This suggests a completely inactive inflammatory state of 
NES-astro at baseline. Calcium responses to ATP and glutamate were evaluated and 
both phaAstro and NES-astro showed response to ATP. Only NES-astro showed 
calcium response to glutamate. Next, the ability of the models to serve as screening 
platforms for apoE secretion were evaluated. Cholesterol and lipid metabolism in the 
brain is regulated by astrocytes, and the lipoprotein transporter protein apoE is 
predominantly produced by astrocytes. Given the strong genetic link between apoE 
isoform and Alzheimer’s disease, apoE is a highly interesting target in drug 
development. As such, a high-throughput compatible pilot screen was set up to 
evaluate apoE secretion after treatment with known apoE inducers. Results showed 
that none of the substances tested induced apoE secretion in all models, highlighting 
that hit-finding depends on the cellular model used. For example, liver X receptor 
(LXR) agonists are well documented apoE enhancers that produced very high 
responses in CCF but did not produce uniform increased apoE secretion in NES-astro 
or phaAstro. Interestingly, substances acting on the cholesterol biosynthesis pathway 
were identified to increase apoE secretion in both phaAstro and NES-astro, while no 
effect was seen in CCF. These results suggested that caution needs to be taken when 
choosing an astrocyte in vitro cell model for screening, especially if primary and 
secondary screens are undertaken with different cell types. In summary, NES-astro 
showed high similarity to phaAstro, demonstrated several functional characteristics 
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and astrocytic markers and represented an astrocytic model with high biological 
relevance.  
 Paper III: Enhanced Xeno-Free Differentiation 
of hiPSC-Derived Astrocytes Applied in a 
Blood-Brain Barrier Model 
To improve astrocyte differentiation and adapt astrocyte differentiation to xeno-free 
conditions, a comparative study was made between differentiating astrocytes on 
murine sarcoma derived laminin (L2020) and human recombinant laminin 521 
(LN521). We showed in Paper I that iPSC-derived BBB models could benefit from 
coculture with iPSC-derived astrocytes, pericytes and neurons. In addition, our 
comparison in Paper II of astrocyte models shows that NES-astro is a more reliable 
astrocyte model than iCellAstro, which was used in the BBB model in Paper I. 
Consequently, the BBB model may benefit from coculture with NES-astro rather than 
iCellAstro. Furthermore, several published models have achieved improvements in 
BBB models using only astrocyte coculture. Our previous data suggest that NES-Astro 
can be differentiated on laminin 521 with similar transcriptional profile to L2020-
differentiated astrocytes, but no functional comparison of xeno-free and conventional 
NES-astro differentiation was performed. Hence, this work was aimed at comparing 
functionality and barrier inducing capacity of astrocytes differentiated from lt-NES on 
L2020 and LN521. Laminins are the most abundant component of the BM, which lines 
the brain blood vessels. In addition to their structural functions, laminins play essential 
roles in the organization of the BM and in the regulation of cell behaviour. Several in 
vitro cell models have shown enhanced functional development when cultured on 
specific laminins. Astrocytes derived on L2020 and LN521 showed expression of 
astrocyte-related proteins and mRNAs such as BLBP, GFAP and S100B. In addition, 
astrocytes differentiated on LN521 had higher expression of GFAP, S100B, 
ALDH1L1, Ang-1 and GDNF mRNAs. Glutamate uptake analysis showed that both 
L2020- and LN521-differentiated astrocytes have functional uptake of glutamate 
through EAAT1 (SLC1A3). However, LN521-differentiated astrocytes had higher 
expression of EAAT1 on both protein and mRNA levels. The reduction in glutamate 
uptake upon inhibition of EAAT1 were greater in two of the biological replicates of 
astrocytes differentiated on LN521 compared to astrocytes differentiated on L2020, 
this could be an effect of the increased protein and mRNA levels of EAAT1. Further 
investigating expression of mRNA involved in the glutamate metabolism revealed that 
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astrocytes differentiated on LN521 had higher expression of the glutamine exporter 
SNAT3. Together with the increased levels of EAAT1 this suggested that the 
glutamate metabolism was affected by differentiation on LN521. Proteins secreted by 
astrocytes have many important functions in the CNS and a large part of the influence 
that astrocytes have on brain endothelial cells is via secreted proteins. Astrocytes 
differentiated on LN521 secreted more Ang-1 and S100b compared to astrocytes 
differentiated on L2020. This is in agreement with increased mRNA levels of Ang-1 
and S100B in astrocytes differentiated on LN521. The capacity of the astrocyte to 
induce barrier properties in a xeno-free BBB model was subsequently investigated. 
iPSC-derived brain endothelial cells were derived using a xeno-free version of the 
protocol used in Paper I and cocultured with astrocytes differentiated on LN521 or 
L2020. Both astrocytes differentiated on LN521 and L2020 improved the barrier 
properties of brain endothelial cells in coculture. No differences were observed in 
TEER, but a slightly lower passive permeability was observed in coculture with L2020 
differentiated astrocytes. Interestingly, brain endothelial cells cocultured with LN521 
astrocytes showed higher expression of VE-cadherin, one of the improvement points 
previously identified for the BBB model in Paper I. Furthermore, the increased 
expression of ABCB1 mRNA and the decreased expression of caveolin 1 (Cav1) in 
brain endothelial cells appeared to depend on coculture with differentiated astrocytes 
and was not observed in coculture with NES. This suggested that coculture with more 
mature astrocytes is beneficial. In conclusion, these results show that astrocytes can be 
derived on LN521 and used in a xeno-free iPSC-derived BBB model in vitro with 
similar results as L2020 derived astrocytes. In addition, astrocytes differentiated on 
LN521 may display a more mature phenotype with a higher secretion of factors 
important for BBB formation in iPSC-derived endothelial cells such as Ang-1. 
 Paper IV: An iPSC-Derived Microphysiological 
Blood-Brain Barrier Model for Permeability 
Screening 
In vitro BBB models have been hampered by lack of physiological structural 
arrangement of the cells and inability to recreate the physical forces that affect brain 
endothelial cells in vivo. To create a more physiological culture setting for brain 
endothelial cells this work was aimed at adapting the BBB model to an MPS. In these 
systems, the cells will be subject to both a 3D culture environment and dynamic flow 
introducing shear stress, both of which have been proven important for functional 
Delsing, Louise 
50 
development of the neurovasculature. Furthermore, to address the need to develop 
BBB models that are compatible with high-throughput screening, the MPS used in this 
study is well-suited for high-throughput applications. An MPS BBB model was created 
by culturing iPSC-derived brain endothelial cells in the Organoplate MPS, which has 
the same format as a regular 384 well culture plate and contains 40 microfluidic units 
per plate. The flow through the Organoplate was bidirectional and gravity-driven. 
Culture conditions of iPSC-derived brain endothelial cells in the Organoplate were 
optimized and BBB-specific marker expression and barrier integrity were analysed. 
The data was compared with data obtained from cultures in the commonly used 
Transwell system (used in Paper I). The iPSC-derived brain endothelial cells showed 
expression of the brain endothelial cell marker proteins ZO-1, Glut-1, occludin and 
claudin-5, and formed leak-tight tube structures in the MPS, which had negligible 
permeability to 4.4kDa dextran and very low permeability to the P-gp substrate 
rhodamine 123. Both the 3D MPS and the static 2D Transwell cultures had low 
permeability of 4.4kDa dextran and rhodamine 123. Comparison of mRNA expression 
of brain endothelial cell-associated markers revealed that mRNA levels of VE-
cadherin, CD31 and BCRP were increase in the MPS culture compared with the 
Transwell culture. Intracellular accumulation of the BCRP substrate Hoechst was 
inhibited by the BCRP inhibitor ko143 in the MPS model but not in the Transwell 
model, suggesting that BCRP activity was dependent on the more physiological culture 
environment of the MPS. To facilitate high-throughput screening, cryopreservation 
and direct seeding of frozen iPSC-derived brain endothelial cells into the MPS were 
evaluated. Brain endothelial cells were cryopreserved and seeded directly into the 
Organoplate without effects on barrier integrity or mRNA marker expression. Finally, 
a pilot screen to identity substances that interact with the efflux transporters P-gp and 
BCRP was performed. Known P-gp and BCRP substrates and inhibitors were 
evaluated in a fluorescence-based assay where the changes in permeability of the 
known P-gp substrate, rhodamine 123, and the known BCRP substrate Hoechst were 
evaluated. The MPS BBB model was able to detect all the P-gp and BCRP inhibitors. 
In addition, it was able to detect two out of three BCRP substrates. Taken together the 
results from this study showed that it was possible to generate a 3D microphysiological 
iPSC-derived BBB model with barrier function similar to Transwell models. Even 
though the permeability was generally higher in the MPS model the permeability 
values were very low for both models. Several brain endothelial cell specific functions 
were enhanced in the MPS model compared with the Transwell model. mRNA 
expression of junction-associated proteins and BCRP were increased. Interestingly, 
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functional BCRP activity was observed in the MPS but not in the Transwell, and 
functional P-gp activity was observed in both MPS and Transwell. Furthermore, thanks 
to the 384wp format of the Organoplate and because it was possible to cryopreserve 
the iPSC-derived brain endothelial cells in an assay-ready state, this MPS model was 
found compatible with high-throughput screening. Consequently, this 
microphysiological model of the BBB provides a promising starting point for using 
iPSC-derived MPS for predicting brain permeability of novel therapeutics. 
  
Delsing, Louise 
52 
  
In vitro models of the blood-brain barrier using iPSC-derived cells 
53 
8 DISCUSSION  
 iPSC-derived blood-brain barrier models 
This thesis follows the trajectory of the BBB modelling field in general. Static 
Transwell models are being replaced by more complex 3D models. There are multiple 
reasons why Transwell cultures are replaced by microfluidic systems. MPS provides a 
more physiologically relevant culture in several aspects, a three-dimensional spatial 
organization of the cells allows for the endothelial cells to form tubes and the 
coculturing cells to interact physically with the basolateral face of the endothelial tube. 
The importance of shear stress in BBB and vasculature development has been 
emphasized in several studies (115, 133, 136) and MPS allows for the addition of flow 
and shear stress. Moreover, there are technical aspects that favour the MPS, for 
example, the number of cells needed to create an MPS model is substantially lower 
and continuous live cell imaging is greatly facilitated in some MPS models compared 
with the Transwell models. However, MPS systems similarly have inherent technical 
drawbacks, the setup of MPS is often very complicated and requires special laboratory 
equipment, TEER measurements are difficult to perform which means that more 
laborious assays are needed to assess paracellular permeability. Finally, the throughput 
of MPS is typically very low.  
The iPSC technology has allowed human cells to be used to a larger extent within BBB 
modelling, overcoming issues with availability and quality of primary cells. Primary 
brain endothelial cells and cell lines are not able to create restrictive barriers in vitro 
(2, 129), as such primary cell models have not served as the gold standard to which 
iPSC-derived models can be compared. Extensive research has been performed to 
improve primary BBB models, for example, through coculture (143), overexpression 
of microRNAs (144) and chemical stimuli (145) with only small improvements in 
barrier restriction potential. Interestingly, iPSC-derived brain endothelial cells are able 
to create restrictive barriers with paracellular permeability similar to that seen in vivo. 
It is still unclear why the iPSC-derived brain endothelial cells are able to recreate the 
phenotype of their primary counterparts in vitro. In Paper I, we performed gene 
expression profiling to elucidate underlying mechanisms of endothelial cell ability to 
restrict permeability. The analysis showed significant changes in the WNT, AKT-Pi3K 
and TNF pathways, and a differential expression of occludin and claudins. 
Specifically, claudin-8 and -19 mRNA expression, which were found to be upregulated 
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by coculture, are associated with reduced permeability (63). Interestingly, we show in 
Paper I that the brain endothelial cell line CMEC/D3 and the iPSC brain endothelial 
cells derived with the non-brain-specific protocol have higher mRNA expression of 
VE-cadherin, CD31 and claudin-5 compared to iPSC brain endothelial cells derived 
with the brain endothelial cell specific protocol. Yet, the non-specific endothelial cells 
and the CMEC/D3 had higher paracellular permeability, hence our results were not 
able to corroborate the previously suggested notion that claudin-5 expression levels 
are a determinant of paracellular permeability (2, 116, 146, 147). When investigating 
occludin, differences in protein expression correlating with paracellular permeability 
were detected, and occludin expression has previously been suggested as a determinant 
of TJ permeability in BBB endothelial cells (2, 68, 69). Furthermore, occludin was 
recently suggested to have a potential role in increasing TEER levels (128). Taken 
together, our results suggest that occludin plays an important role in the iPSC derived 
endothelial cells ability to restrict paracellular permeability.  
Of note, in Paper II the baseline secretion of cytokines was found to be substantially 
higher in iCellAstro compared to NES-astro. Interestingly, it was recently reported that 
addition of inflammatory cytokines reduced ZO-1 expression and increased 
permeability in an iPSC-derived BBB model (133). Consequently, it is reasonable to 
speculate that the BBB models in Paper I and Paper III are affected accordingly, as 
iCellAstro was used in Paper I and NES-astro was used in Paper III, however this was 
not directly compared.  
 Comparison to other iPSC-derived blood-brain 
barrier models 
During recent years, there has been a rapid increase in iPSC-derived BBB models. 
iPSC-derived BBB models have developed into tools for investigation of drug 
substance permeability studies similar to the one in Paper I (87, 116, 118, 119, 133), 
disease modelling (7, 99, 121-123) and modelling of BBB disruption (124-127). BBB 
models developed in this thesis are comparable to previously published models, both 
in marker expression and barrier restriction. As discussed in Paper I, TEER values 
obtained of ~ 1250Ohm x cm2 in the coculture were lower than TEER values reported 
for similar models of up to ~2500Ohm x cm2 (116) and ~3000Ohm x cm2 (90, 117) 
but higher than some other reported TEER values of ~500Ohm x cm2 (93). The inverse 
relationship between TEER value and permeability has been shown to disappear at 
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higher TEER levels in iPSC-derived endothelial cells. Threshold values where a higher 
TEER no longer corresponds to a lower permeability were found to be 500Ohm x cm2 
for the small molecule sodium and 900Ohm x cm2 for a large molecule IgG (119). A 
similar study in an animal-derived BBB in vitro model concluded that a TEER value 
of above 500Ohm x cm2 only had marginal effects on mannitol permeability (148). 
Small differences in TEER were observed between different iPSC lines and variations 
between lines in the same experiment are expected, likely due to different donors and 
methods of deriving the iPSCs. The TEER measurement is an important tool for 
assessing paracellular tightness and restricted permeability in the paracellular space is 
of the highest importance for accurate modelling of any transport across the BBB. 
However, above approximately 1000Ohm x cm2 the actual TEER value is of little 
importance. In vivo TEER values are very difficult to measure due to the invasive 
nature of the techniques and requirement of putting electrodes on either side of the 
BBB without disrupting it. Despite this, TEER values for vertebrates have been 
obtained and values across rat and frog brain endothelial cells have been measured in 
the range of 1200–1900Ohm x cm2 (15, 149). In summary, TEER values obtained in 
iPSC-derived BBB models are similar to the in vivo TEER and exceed the critical 
value for paracellular permeability restriction. 
Only a handful of studies have investigated the permeability of drug substances across 
iPSC-derived BBB models, but many different substances have been tested in 
permeability studies. Some studies display a significant distinction between CNS 
permeable and non-CNS permeable substances similar to that in Paper I (116, 118, 
119, 133). Substances that have been tested in more than one model include atenolol, 
propranolol, caffeine and cimetidine. Atenolol was reported to have a permeability of 
approximately 5, 8 and 11 x 10−6cm/s (Paper I, (118, 119)), propranolol 
approximately 20 and 40 x 10−6cm/s (Paper I, (119)), caffeine approximately 60 and 
100 x 10−6cm/s (116, 119) and cimetidine approximately 1 and 10  x 10−6cm/s (118, 
119). In summary, permeability values reported for drug substances are comparable 
between published iPSC-derived BBB models. However, there is a need to further 
investigate the permeability of drug substances in iPSC-derived BBB models and to 
standardize permeability assays to facilitate comparisons between models.  
Recently, several iPSC-derived BBB models in MPS have been reported, both 
monoculture systems (135, 136, 139) and coculture systems with pericytes and/or 
neural cell types (95, 117, 133, 134). In these studies coculture with only pericytes did 
not affect permeability (117), but coculture with astrocytes, with or without pericytes 
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and neurons, resulted in reduced permeability (95, 133, 134) or increased impedance 
(132). Permeability measurements using fluorescently labelled dextrans show that 
these models have very low permeability, several models reported a permeability of 2-
4 x 10−7cm/s (95) or below detection limit for 10kDa dextrans (117, 135). 
Permeability for 4kDa dextran and 3kDa dextran was reported to be in the range of 
single digit 10−7cm/s and 1-3 x10−7cm/s. These permeability assessments 
correspond well to the ~5 x 10−7cm/s permeability of 4,4kDa observed in Paper IV. 
Permeability for 4kDa dextrans across in vivo rat cerebral microvasculature has been 
reported to be the 9.2 x 10−7cm/s (130). Additionally, experiments in Paper IV 
showed P-gp and BCRP activity in the MPS, similarly, other iPSC-derived BBB MPS 
models have reported P-gp activity (132, 133, 135) and BCRP activity (132). A 
rhodamine 123 permeability of approximately 0,2-5 x 10−7cm/s was observed for the 
MPS in Paper IV, very similar rhodamine123 permeabilities of 1-2 x 10−7cm/s have 
been observed in other iPSC-derived BBB MPS (135). Notably, the expression of 
several brain endothelial cell markers has previously been shown to depend on flow 
(133). Similarly, the expression of several endothelial cell markers was upregulated in 
the MPS model compared to the Transwell model in Paper IV, suggesting that this 
effect may indeed be flow dependant. Consequently, the MPS model developed in 
Paper IV showed very similar permeability properties to other iPSC-derived BBB MPS 
and lower permeability compared with in vivo rat data. However, the model may still 
benefit from an astrocyte coculture. An important difference between the MPS model 
reported in Paper IV and other iPSC-derived MPS BBB models is the compatibility 
with high-throughput screening.  
 Efflux assessment in iPSC-derived blood-brain 
barrier models 
A major requirement for any BBB model to be used in permeability assessments for 
safety evaluation of novel drug molecules is the expression and function of the two 
main efflux transporters BCRP and P-gp. Evaluation of P-gp and BCRP interactions 
are needed for safety studies and are important assessments of drug-drug interactions. 
P-gp and BCRP expression and activity were measured in the BBB models in Papers 
I, III and IV. Paper I show that both P-gp and BCRP mRNA levels increased after 
coculture. No differences in P-gp activity could be detected between monoculture and 
coculture, however, BCRP activity was only detected in coculture. Paper III shows that 
P-gp mRNA increases when endothelial cells are cocultured with differentiated 
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astrocytes compared to coculture with the neuro epithelial stem cells (lt-NES). No 
change was observed in the mRNA expression of BCRP between cocultures with 
differentiated astrocytes and NES. Paper IV, examining iPSC-derived endothelial cell 
monocultures in MPS and Transwell, showed that BCRP mRNA expression increased 
in MPS compared to Transwell and that BCRP activity was detectable in MPS but not 
in Transwell. P-gp mRNA expression and activity was not found to be different 
between Transwell and MPS. In summary, P-gp is expressed and functional in iPSC-
derived endothelial cells and does not require coculture or culture in MPS for its 
activity to be detectable. However, BCRP activity is not detectable in iPSC-derived 
endothelial cells in static monoculture. Coculture and MPS culture both increased 
BCRP mRNA expression and either coculture or MPS culture is required for detection 
of functional BCRP efflux. This is in agreement with studies concluding that iPSC-
derived brain endothelial cells display active efflux by P-gp which is unaffected by 
coculture (93, 116, 128). Most published iPSC-derived BBB models do not examine 
BCRP activity, but similarly to our results one study reported active BCRP in coculture 
(87). Other studies reported both active P-gp and BCRP in monocultures of iPSC-
derived brain endothelial cells. However, these results were obtained using a different 
BCRP substrate (131) and after using an adjusted differentiation protocol (91). 
Similarly to the results in Paper IV, other iPSC BBB models have shown both active 
P-gp (132, 135) and active BCRP (132) in monoculture MPS. However, no direct 
comparisons to BCRP activity in 2D culture were made in these studies. In conclusion, 
our data suggest that any assay of BCRP-mediated permeability requires a more 
complex model with either astrocyte coculture or culture in an MPS. 
 Blood-brain barrier phenotype of iPSC-derived 
endothelial cells 
Recently, the endothelial identity of iPSC-derived endothelial cells has been 
questioned, and claims have been made that these cells are actually neuroepithelium 
(150). From the gene expression analysis in Paper I, it was concluded that iPSC-
derived brain endothelial cells may display a mixed endothelial epithelial phenotype. 
However, as exemplified in Paper I and IV, the in vitro barrier restriction capacity of 
these cells is still highly superior to other brain endothelial cells from immortalized 
cell lines, primary cells and iPSC endothelial cells derived with other protocols. In 
addition, we showed in Paper I that the expression of the important efflux transporter 
BCRP was higher in iPSC-derived brain endothelial cells compared to iPSC 
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endothelial cells derived with a non-specific protocol. Even though the protein 
expression signature of brain endothelial cells derived from iPSCs with the brain 
endothelial cell specific protocol may be mixed, these cells display exceptionally high 
tightness and expression of BBB specific transporters. As such, they are a very relevant 
human model system that can be used for permeability assessments. In vitro cell 
models will never be able to recapitulate the full complexity of the in vivo biology and 
in the interest of usability, models need to be simplified versions of the modelled 
process or structure. As discussed in the introduction, the BBB is a complex multi-
component structure that is likely to have several critical requirements for in vitro 
culture to correctly model its functions. Enhancing the brain endothelial cell phenotype 
of iPSC-derived endothelial cells and optimization of iPSC-derived BBB model is far 
from complete. Improvement of models is an ongoing process. Likely, there are 
opportunities for optimization of the differentiation and culture processes, which could 
be exploited to further improve the BBB phenotype of the model and produce iPSC-
derived brain endothelial cells with more similar transcription signature to brain 
endothelial cells in vivo. In addition, there is a great need to further characterize the 
capacity of iPSC-derived BBB models to be used in permeability assessments. More 
information about activity and expression is required for many of the transporter 
proteins active at the BBB.  
 Brain permeability prediction in drug discovery 
The current strategy for CNS permeability assessment in drug discovery relies on, first, 
determining if the substance is an efflux transporter substrate and second, determining 
the in vivo brain exposure in rodents. This is commonly preceded by in silico 
modelling of BBB permeability used in the lead generation process. Efflux transporter 
assays are generally performed using the low permeability human epithelial colorectal 
adenocarcinoma cell line (Caco-2) and Madin-Darby canine kidney cells 
overexpressing efflux transporter P-gp (MDCK-MRD1) line in Transwell systems 
relatively early in the drug discovery process. Later, in vivo rodent permeability 
assessments are performed. The ratio of the total brain concentration to total plasma 
concentration at equilibrium combined with the fraction unbound in brain and fraction 
unbound in plasma is determined. After infusion the concentrations in blood and in 
whole brain homogenate are analysed, brain binding is typically assessed by incubating 
rat brain slices with a compound cocktail. These methods are very low throughput and 
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require several animals per data point. Hence, they are performed at the last stages of 
drug development before clinical trials.  
iPSC-derived BBB models described in this thesis could replace the Caco-2 and 
MDCK-MDR1 lines in efflux transporter assays. In contrast to Caco-2 and MDCK cell 
lines, these iPSC-derived BBB models contain human brain-specific cells with 
expression of many BBB transporters lacking in the Caco-2 and MDCK-MDR1 lines 
which originate from colon and kidney respectively. Using human brain-specific cells 
provides an opportunity to evaluate other transport routs in addition to efflux transport. 
Additionally, using microfluidic iPSC-derived BBB models allows for higher 
throughput analysis than a Caco-2 or MDCK-MDR1 Transwell assay. Consequently, 
a microfluidic iPSC-derived BBB model have the possibility to provide important 
information earlier in the drug discovery process. Earlier prediction of brain exposure 
by a combination of mechanisms rather than efflux only would generate better 
translatability to the rodent in vivo models, causing fewer undesired compounds to 
make it as far as the in vivo assay. If fewer substances require in vivo model testing it 
would both reduce the number of animals needed for testing and provide a more cost-
efficient process. Even though it would be desirable to replace in vivo animal testing 
completely, that is not likely to transpire in the near future. Due to the inability of 
present in vitro cell models to estimate brain-binding and metabolism, which govern 
the unbound drug concentration. These models are not able to predict the amount of 
substance which exerts the physiological function, i.e. the unbound fraction. 
Furthermore, there are regulatory requirements for animal testing before human trials 
and human data to verify an in vitro model to a satisfactory extent is lacking. 
Consequently, CNS permeability assessment in drug discovery would benefit from the 
use of an iPSC-derived BBB model in efflux assays. However, for the added benefit 
of modelling additional transport processes a more extensive analysis of what transport 
routes are accurately modelled in the iPSC-derived BBB model would need to be 
performed beforehand. Such analysis should include gene and protein expression of 
transporters together with functional analysis of transport compared to human in vivo 
data. The major challenges would be finding validated substrates for all transporters 
and the large amount of work it would take to generate the corresponding human in 
vivo data. However, recent advances in integrated transcriptomic and proteomic 
analysis and non-invasive brain PET imaging provides possible strategies to overcome 
these challenges.  
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 Limitations 
There are differences between iPSC lines depending on, for example, their genetic 
background, what method was used for generation and culture conditions. In addition, 
commercially available iPSC lines originate mostly from Caucasian male individuals. 
This limits the ability to draw general conclusions. In this work, multiple iPSC lines 
have been used in experiments to allow for more general conclusions. However, the 
diversity of the genetic background in the lines used was still limited. There are further 
limitations to the use of iPSC-derived cell types as they generally display an immature 
or foetal-like phenotype. Hence, characterization of the function investigated needs to 
be thorough. In this work complementary analysis of RNA, protein and function 
increases confidence in cell type identity of iPSC-derived cell types. However, 
analyses on all levels were not performed for all experiments, which constitutes a 
limitation of what conclusions can be drawn. Specifically, the pathway analysis and 
gene expression analysis in Paper I needs experimental verification to allow more 
definite conclusions. Investigating differences in pathways and processes by 
evaluation of annotated mRNAs can provide indication of changes because most of the 
components of the pathway or process are evaluated, but experimental verification is 
still needed.  
Primary brain endothelial cells do not retain BBB phenotype in vitro, hence, they are 
not suitable for comparison. Additionally, BBB permeability has historically required 
invasive sampling and human data is very rare. The difficulties in comparing results 
with both human primary cell culture and human in vivo data are major limitations of 
this work. Many of the results from experiments in this work need further experimental 
verification and confirmation via in vivo studies. 
A large part of CNS permeability and availability assessment of drug substances are 
measurements of unbound drug concentrations in the brain. The unbound drug 
concentration is essentially the active concentration available to exert its physiological 
effect. The permeability measurements performed in the in vitro models in this thesis 
do not consider the binding and metabolism that may occur in the CNS affecting the 
concentration of substance available in the CNS in vivo. 
Models in this work were evaluated based on BBB-specific phenotype, however, no 
challenges to the BBB were performed. Cocultures have been shown to increase the 
tolerance of BBB models to challenges that could alter their permeabilities, but no such 
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affects were investigated in these studies. Consequently, coculture may have additional 
effects only detectable under stress conditions not detected in these studies.  
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9 CONCLUSIONS 
In this thesis, iPSC-derived models of the BBB were developed and evaluated. Model 
improvements were generated by evaluation of different methods to derive endothelial 
cells and astrocytes from iPSC as well as evaluating different culture systems. A 
microfluidic model was developed, which is compatible with efflux transporter assays 
in high-throughput. The BBB models displayed a barrier phenotype in expression of 
proteins and mRNA associated with brain endothelial cells. Functional testing showed 
that the model exhibits selective permeability of both passively diffused substances 
and substances that interact with brain-specific transporters. These properties were 
comparable to other iPSC-derived models and in vivo permeability restriction. The 
outcomes provide new insight into molecular mechanisms that influence iPSC-derived 
BBB models’ ability to restrict permeability and to model requirements for 
permeability assessments. The models developed in this thesis provide a promising 
starting point for the use of iPSC-derived BBB models in drug discovery and 
permeability assessments. In addition, the work highlights remaining questions and 
challenges for iPSC-derived BBB models that need to be addressed for the models to 
be useful in a wider range of applications. In particular, there is a need for standardizing 
permeability assessment assays across models and to increase the number of 
comparisons to in vivo human data. 
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10 FUTURE PERSPECTIVES 
Building on the work in this thesis there are several opportunities to further 
characterize and improve iPSC-derived BBB models. In Paper IV, we showed that the 
microfluidic model has some improved barrier restriction properties and can be 
implemented in high-throughput assays. However, many questions remain about what 
changes can be observed in the microphysiological model compared to the static 
Transwell culture. A deeper investigation of how the culture environment and the shear 
stress in the microphysiological model affect the cells would be highly interesting. A 
genome wide expression profiling of mRNA and protein comparing the two models 
would allow for an analysis of what BBB properties are affected by MPS culture and 
could help direct further mechanistic studies. Additionally, establishing a coculture 
model in the MPS system may further improve the BBB model in a similar manner 
seen in many Transwell static models. Indeed, reduced permeability was observed in 
a recent iPSC-derived BBB MPS model after coculture with astrocytes, neurons and 
neural progenitors (133). By applying pericytes and astrocytes in the gel compartment 
of the MPS system, established in Paper IV, a contact coculture, similar to that in vivo 
could be formed. An isogenic BBB model could be created using the recently 
published protocol for derivation of brain-specific pericytes (99) and using the xeno-
free derivation of astrocytes described in Paper III. The collagen gel used for gel 
casting in the MPS and the brain pericyte protocol contain some animal components 
and needs to be modified to xeno-free conditions before a fully defined, isogenic iPSC 
BBB model can be derived. Recently, a serum free protocol for differentiation to brain 
endothelial cells was published which could be adopted in future BBB models (91). A 
xeno-free BBB model would likely reduce variability and be an important optimization 
step for the coculture model to be used in high-throughput permeability assays. 
The number of iPSC-derived models of the BBB is rapidly increasing, but the use of 
iPSC-derived BBB models in drug discovery is still limited. While using iPSC-derived 
cells allow for studying models with a diseases background and comparing to 
genetically modified isogenic controls it is still likely that the first large-scale use of 
these models will be permeability assessment. Recreating a disease phenotype, in vitro, 
in a complex multicellular system such as the BBB is still a great challenge. Major 
issues include recreating the specific structure of the BBB that is needed for its 
function, optimizing culture conditions to several cell types, variability in cell culture 
and differentiation, and providing a biologically relevant model in a usable screening 
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format. Creating a model for permeability assessment may still require complex in 
vitro cultures, but quality control standardization could more easily be adopted for one 
functional readout than a complex multifaceted disease phenotype. Standardizing the 
characterization and validation of models would enhance their application and 
adoption within drug discovery. Such standardization may include establishing 
analytical performance standards for models and a defined set of reference compounds 
that can demonstrate desired outcome and be compared across different models and 
labs. The lack of human in vivo permeability data for comparison is a major hurdle in 
model development. To establish a reference set of compounds for permeability 
testing, human in vivo data needs to be obtained so that comparisons can be made. In 
recent years, quantitative imaging permeability assessments in humans have increased 
and provide a non-invasive way of measuring brain penetration of substances. The 
increasing amount of human in vivo data generated with this method may facilitate 
human in vivo to in vitro comparisons in the future. After all, for these models to be 
successfully adopted by the pharmaceutical industry they need to have good predictive 
capacity, sufficient throughput and compatibility with automated handling, low 
variability and ease of use.  
There are many potential future applications of iPSC-derived BBB models, especially 
in modelling the complex cellular cross talk between different cell types at the BBB. 
There have been substantial investments in research on how neuronal cells and 
pericytes influence the BBB formation, function, and maintenance. However recent 
literature suggests that endothelial cells at the BBB may play a significant role in the 
communication between the peripheral organs and the CNS, both via the proteins 
secreted by the endothelial cells into the CNS and regulation of the controlled transport 
across the BBB. It has been shown, in an iPSC-derived system, that the vasculature 
has specific maturation effects on spinal motor neurons (151), and in the adult central 
nervous system the vasculature regulates neural stem cell behaviour by providing 
circulating and secreted factors. Age-related decline of neurogenesis and cognitive 
function is associated with reduced blood flow and decreased numbers of neural stem 
cells. Therefore, restoring the functionality of the CNS vasculature could counteract 
some of the negative effects of aging. It has been shown that factors found in young 
blood induce vascular remodelling, culminating in increased neurogenesis and 
improved olfactory discrimination in aging mice. Remarkably, one of the identified 
substances contributing to these effects does so without entering the CNS itself (152). 
Remodelling of the brain vasculature may function as a mediator in providing benefits 
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such as increased neurogenesis and improved cognition and hence, brain endothelial 
cell secreted proteins may be of high importance. iPSC-derived BBB coculture models 
could be a useful tool to further explore how signalling from the brain endothelium 
affects neurons and other CNS components.  
Another highly interesting feature of the BBB, not examined in this work, is how the 
nutrient supply to the brain across the BBB is affected in aging and neurodegenerative 
disorders. The brain accounts for 20% of all energy consumption at rest. Glut-1 is 
responsible for a majority of the glucose uptake from the blood to the brain and brain 
glucose uptake correlates with Glut-1 levels (71, 153). As shown in Papers I, III and 
IV the high Glut-1 level in the BBB are recapitulated in the iPSC-derived model and 
thus it may be a good candidate model for studies of the Glut-1 mediated transport. 
Indeed, active glucose uptake through Glut-1 has been shown in iPSC-derived brain 
endothelial cells derived with similar methods (154). Ideally, iPSC-derived cells from 
a disease background and their isogenic controls could be used for such studies. 
Mutations in the Glut-1 gene SLC1A2, also known as Glut-1 deficiency syndrome 
cause seizures, delayed development and microencephaly, due to low CSF glucose 
levels (155). Reduction in Glut-1 levels and glucose transport have been observed in 
animal models of both aging and AD (156, 157) and in AD patients (158). 
Furthermore, glucose uptake is reduced in individuals with genetic risk for AD (159). 
Glucose metabolism is reduced in individuals with a family history of AD (160) and 
cognitively normal individuals who later develop AD (161). Consequently, reduced 
glucose transport has been suggested to precede AD onset and affect the progression, 
BBB stability and pathology in AD (162). Increasing the understanding of glucose 
transport deficits in healthy and diseased individuals could be useful both in terms of 
earlier diagnosis and exploration of new therapeutic strategies.  
In conclusion, the iPSC-derived BBB model systems are still in their early 
development, this is especially true for MPS. These systems have great capacity to 
advance into highly sophisticated models and there will indubitable be many new 
applications for these systems in the future. However, many challenges still remain, 
particularly with respect to reproducibility and recreation of multifaceted phenotypes 
in vitro with increasing complexity in the models. An important first step towards 
improved BBB models would be to establish analytical performance standards that can 
be compared with in vivo human data and across model systems. 
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